Siddique AB, Kilgore PCSR, Tajmim A, Singh SS, Meyer SA, Jois SD, Cvek U, Trutschl M, Sayed KAE.,
(-)-Oleocanthal as a Dual c-MET-COX2 Inhibitor for the Control of Lung Cancer, Nutrients. 2020 Jun 11;12(6):1749. doi: 10.3390/nu12061749.
Masoodi, K. Z., Ramos Garcia, R., Pascal, L. E., Wang, Y., Ma, H. M., O'Malley, K., . . . Wang, Z. (2013).,
5alpha-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models., Endocrinology, 154(7), 2296-2307. doi:10.1210/en.2012-2077 [doi]
Yang, Hailing; Shu, Zhang; Jiang, Yongying; Mao, Weiqun; Pang, Lan; Redwood, Abena; Jeter-Jones, Sabrina L; Jennings, Nicholas B; Ornelas, Argentina; Zhou, Jinhua; Rodriguez-Aguayo, Cristian; Bartholomeusz, Geoffrey; Iles, LaKesla R; Zacharias, Niki M; Millward, Steven W; Lopez-Berestein, Gabriel; Le, Xiao-Feng; Ahmed, Ahmed A; Piwnica-Worms, Helen; Sood, Anil K; Bast, Robert C; Lu, Zhen,
6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers, Clinical cancer research : an official journal of the American Association for Cancer Research Vol.25, 2019
Marayati R, Bownes LV, Stafman LL, Williams AP, Quinn CH, Atigadda V, Aye JM, Stewart JE, Yoon KJ, Beierle EA.,
9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts, Transl Oncol. 2021 Jan;14(1):100893. doi: 10.1016/j.tranon.2020.100893. Epub 2020 Sep 30.
Marayati R, Bownes LV, Stafman LL, Williams AP, Quinn CH, Atigadda V, Aye JM, Stewart JE, Yoon KJ, Beierle EA.,
9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts, Transl Oncol. 2021 Jan;14(1):100893. doi: 10.1016/j.tranon.2020.100893. Epub 2020 Sep 30.
Deng, Y., Wang, Z., Zhang, F., Qiao, M., Yan, Z., Wei, Q., . . . Zhang, J. (2016),
A blockade of IGF signaling sensitizes human ovarian cancer cells to the anthelmintic niclosamide-induced anti-proliferative and anticancer activities, Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 39(3), 871-888. doi:10.1159/000447797 [doi]
Kuznik NC, Solozobova V, Lee II, Jung N, Yang L, Nienhaus K, Ntim EA, Rottenberg JT, Muhle-Goll C, Kumar AR, Peravali R, Gräßle S, Gourain V, Deville C, Cato L, Neeb A, Dilger M, Cramer von Clausbruch CA, Weiss C, Kieffer B, Nienhaus GU, Brown M, Bräse S, Cato ACB.,
A chemical probe for BAG1 targets androgen receptor-positive prostate cancer through oxidative stress signaling pathway, iScience. 2022 Mar 31;25(5):104175. doi: 10.1016/j.isci.2022.104175. eCollection 2022 May 20.
Luderer, M. J., Muz, B., de la Puente, P., Chavalmane, S., Kapoor, V., Marcelo, R., . . . Azab, A. K. (2016),
A hypoxia-targeted boron neutron capture therapy agent for the treatment of glioma., Pharmaceutical Research, 33(10), 2530-2539. doi:10.1007/s11095-016-1977-2 [doi]
Tian Q, Zhang P, Wang Y, Si Y, Yin D, Weber CR, Fishel ML, Pollok KE, Qiu B, Xiao F, Chong AS.,
A novel triptolide analog downregulates NF-kB and induces mitochondrial apoptosis pathways in human pancreatic cancer., Elife. 2023 Oct 25;12. pii: e85862. doi: 10.7554/eLife.85862. [Epub ahead of print]
Shivange G, Mondal T, Lyerly E, Bhatnagar S, Landen CN, Reddy S, Kim J, Doan B, Riddle P, Tushir-Singh J.,
A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors, Cell Rep. 2021 Nov 2;37(5):109953. doi: 10.1016/j.celrep.2021.109953.
Hight, M. R., Cheung, Y. Y., Nickels, M. L., Dawson, E. S., Zhao, P., Saleh, S., . . . Manning, H. C. (2014).,
A peptide-based positron emission tomography probe for in vivo detection of caspase activity in apoptotic cells., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 20(8), 2126-2135. doi:10.1158/1078-0432.CCR-13-2444 [doi]
Dey, J., Kerwin, W. S., Grenley, M. O., Casalini, J. R., Tretyak, I., Ditzler, S. H., . . . Klinghoffer, R. A. (2016),
A platform for rapid, quantitative assessment of multiple drug combinations simultaneously in solid tumors in vivo., PloS One, 11(6), e0158617. doi:10.1371/journal.pone.0158617 [doi]
Green, D. J., Orgun, N. N., Jones, J. C., Hylarides, M. D., Pagel, J. M., Hamlin, D. K., . . . Press, O. W. (2014),
A preclinical model of CD38-pretargeted radioimmunotherapy for plasma cell malignancies., Cancer Research, 74(4), 1179-1189. doi:10.1158/0008-5472.CAN-13-1589 [doi]
Neiveyans, Madeline; Melhem, Rana; Arnoult, Christophe; Bourquard, Thomas; Jarlier, Marta; Busson, Muriel; Laroche, Adrien; Cerutti, Martine; Pugnière, Martine; Ternant, David; Gaborit, Nadège; Chardès, Thierry; Poupon, Anne; Gouilleux-Gruart, ValÊrie; Pèlegrin, Andre; Poul, Marie-Alix;,
A recycling anti-transferrin receptor-1 monoclonal antibody as an efficient therapy for erythroleukemia through target up-regulation and antibody-dependent cytotoxic effector functions, mAbs Vol.11, 2019
Santich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK.,
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy, Clin Cancer Res. 2020 Sep 21. doi: 10.1158/1078-0432.CCR-20-2150. Online ahead of print.
Santich BH, Cheal SM, Ahmed M, McDevitt MR, Ouerfelli O, Yang G, Veach DR, Fung EK, Patel M, Burnes Vargas D, Malik AA, Guo HF, Zanzonico PB, Monette S, Michel AO, Rudin CM, Larson SM, Cheung NK.,
A Self-Assembling and Disassembling (SADA) Bispecific Antibody (BsAb) Platform for Curative Two-step Pretargeted Radioimmunotherapy, Clin Cancer Res. 2021 Jan 15;27(2):532-541. doi: 10.1158/1078-0432.CCR-20-2150. Epub 2020 Sep 21.
Roy, L. D., Dillon, L. M., Zhou, R., Moore, L. J., Livasy, C., El-Khoury, J. M., . . . Mukherjee, P. (2017).,
A tumor specific antibody to aid breast cancer screening in women with dense breast tissue., Genes & Cancer, 8(3-4), 536-549. doi:10.18632/genesandcancer.134 [doi]
Kim, S. S., Rait, A., Kim, E., Pirollo, K. F., & Chang, E. H. (2015).,
A tumor-targeting p53 nanodelivery system limits chemoresistance to temozolomide prolonging survival in a mouse model of glioblastoma multiforme., Nanomedicine : Nanotechnology, Biology, and Medicine, 11(2), 301-311. doi:10.1016/j.nano.2014.09.005 [doi]
Formisano, Luigi; Lu, Yao; Servetto, Alberto; Hanker, Ariella B; Jansen, Valerie M; Bauer, Joshua A; Sudhan, Dhivya R; Guerrero-Zotano, Angel L; Croessmann, Sarah; Guo, Yan; Ericsson, Paula Gonzalez; Lee, Kyung-Min; Nixon, Mellissa J; Schwarz, Luis J; Sanders, Melinda E; Dugger, Teresa C; Cruz, Marcelo Rocha; Behdad, Amir; Cristofanilli, Massimo; Bardia, Aditya; OShaughnessy, Joyce; Nagy, Rebecca J; Lanman, Richard B; Solovieff, Nadia; He, Wei; Miller, Michelle; Su, Fei; Shyr, Yu; Mayer, Ingrid A; Balko, Justin M; Arteaga, Carlos L;,
Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer., Nature communications Vol.10, 2019
Tansi, F. L., Ruger, R., Bohm, C., Steiniger, F., Kontermann, R. E., Teichgraeber, U. K., . . . Hilger, I. (2017).,
Activatable bispecific liposomes bearing fibroblast activation protein directed single chain fragment/Trastuzumab deliver encapsulated cargo into the nuclei of tumor cells and the tumor microenvironment simultaneously., Acta Biomaterialia, 54, 281-293. doi:S1742-7061(17)30203-9 [pii]
Young, N. R., Soneru, C., Liu, J., Grushko, T. A., Hardeman, A., Olopade, O. I., . . . Cohen, E. E. (2015).,
Afatinib efficacy against squamous cell carcinoma of the head and neck cell lines in vitro and in vivo., Targeted Oncology, 10(4), 501-508. doi:10.1007/s11523-014-0353-6 [doi]
Ziegler, J., Bastian, A., Lerner, M., Bailey-Downs, L., Saunders, D., Smith, N., . . . Towner, R. A. (2017).,
AG488 as a therapy against gliomas., Oncotarget, 8(42), 71833-71844. doi:10.18632/oncotarget.18284 [doi]
Gomes AP, Ilter D, Low V, Endress JE, Fernández-García J, Rosenzweig A, Schild T, Broekaert D, Ahmed A, Planque M, Elia I, Han J, Kinzig C, Mullarky E, Mutvei AP, Asara J, de Cabo R, Cantley LC, Dephoure N, Fendt SM, Blenis J.,
Age-induced accumulation of methylmalonic acid promotes tumour progression, Nature. 2020 Sep;585(7824):283-287. doi: 10.1038/s41586-020-2630-0. Epub 2020 Aug 19.
Dunn S, Eberlein C, Yu J, Gris-Oliver A, Ong SH, Yelland U, Cureton N, Staniszewska A, McEwen R, Fox M, Pilling J, Hopcroft P, Coker EA, Jaaks P, Garnett MJ, Isherwood B, Serra V, Davies BR, Barry ST, Lynch JT, Yusa K.,
AKT-mTORC1 reactivation is the dominant resistance driver for PI3Kβ/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors, Oncogene. 2022 Nov;41(46):5046-5060. doi: 10.1038/s41388-022-02482-9. Epub 2022 Oct 14.
Sun Y, Meyers BA, Czako B, Leonard P, Mseeh F, Harris AL, Wu Q, Johnson S, Parker CA, Cross JB, Di Francesco ME, Bivona BJ, Bristow CA, Burke JP, Carrillo CC, Carroll CL, Chang Q, Feng N, Gao G, Gera S, Giuliani V, Huang JK, Jiang Y, Kang Z, Kovacs JJ, Liu CY, Lopez AM, Ma X, Mandal PK, McAfoos T, Miller MA, Mullinax RA, Peoples M, Ramamoorthy V, Seth S, Spencer ND, Suzuki E, Williams CC, Yu SS, Zuniga AM, Draetta GF, Marszalek JR, Heffernan TP, Kohl NE, Jones P.,
Allosteric SHP2 Inhibitor, IACS-13909, Overcomes EGFR-Dependent and EGFR-Independent Resistance Mechanisms toward Osimertinib, Cancer Res. 2020 Nov 1;80(21):4840-4853. doi: 10.1158/0008-5472.CAN-20-1634. Epub 2020 Sep 14.
Zhang, R., Pan, D., Cai, X., Yang, X., Senpan, A., Allen, J. S., . . . Wang, L. V. (2015),
alphaVbeta3-targeted copper nanoparticles incorporating an sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment., Theranostics, 5(2), 124-133. doi:10.7150/thno.10014 [doi]
Bush, T. L., Payton, M., Heller, S., Chung, G., Hanestad, K., Rottman, J. B., . . . Radinsky, R. (2013),
AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models, Molecular Cancer Therapeutics, 12(11), 2356-2366. doi:10.1158/1535-7163.MCT-12-1178 [doi]
Asundi, J., Crocker, L., Tremayne, J., Chang, P., Sakanaka, C., Tanguay, J., . . . Firestein, R. (2015),
An antibody-drug conjugate directed against lymphocyte antigen 6 complex, locus E (LY6E) provides robust tumor killing in a wide range of solid tumor malignancies., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(14), 3252-3262. doi:10.1158/1078-0432.CCR-15-0156 [doi]
Citron, F., Armenia, J., Franchin, G., Polesel, J., Talamini, R., D'Andrea, S., . . . Baldassarre, G. (2017),
An integrated approach identifies mediators of local recurrence in head and neck squamous carcinoma, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(14), 3769-3780. doi:10.1158/1078-0432.CCR-16-2814 [doi]
Zhang, F., Li, Y., Zhang, H., Huang, E., Gao, L., Luo, W., . . . Ji, P. (2017).,
Anthelmintic mebendazole enhances cisplatin's effect on suppressing cell proliferation and promotes differentiation of head and neck squamous cell carcinoma (HNSCC)., Oncotarget, 8(8), 12968-12982. doi:10.18632/oncotarget.14673 [doi]
Miles, L. A., Burga, L. N., Gardner, E. E., Bostina, M., Poirier, J. T., & Rudin, C. M. (2017).,
Anthrax toxin receptor 1 is the cellular receptor for seneca valley virus., The Journal of Clinical Investigation, 127(8), 2957-2967. doi:10.1172/JCI93472 [doi]
Moody, G., Belmontes, B., Masterman, S., Wang, W., King, C., Murawsky, C., . . . Beltran, P. J. (2016).,
Antibody-mediated neutralization of autocrine Gas6 inhibits the growth of pancreatic ductal adenocarcinoma tumors in vivo, International Journal of Cancer, 139(6), 1340-1349. doi:10.1002/ijc.30180 [doi]
Tabernero, J., Chawla, S. P., Kindler, H., Reckamp, K., Chiorean, E. G., Azad, N. S., . . . Baselga, J. (2015).,
Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab., argeted Oncology, 10(1), 65-76. doi:10.1007/s11523-014-0315-z [doi]
Zhang S, Zhao L, Guo M, Liu P, Li S, Xie W, Tian AL, Pol JG, Chen H, Pan H, Mao M, Li Y, Zitvogel L, Jin Y, Kepp O, Kroemer G.,
Anticancer effects of ikarugamycin and astemizole identified in a screen for stimulators of cellular immune responses., J Immunother Cancer. 2023 Jul;11(7). pii: e006785. doi: 10.1136/jitc-2023-006785.
Li, X., Wu, J. B., Chung, L. W., & Huang, W. C. (2015).,
Anti-cancer efficacy of SREBP inhibitor, alone or in combination with docetaxel, in prostate cancer harboring p53 mutations., Oncotarget, 6(38), 41018-41032. doi:10.18632/oncotarget.5879 [doi]
Yan, H., Kapoor, V., Nguyen, K., Akers, W. J., Li, H., Scott, J., . . . Hallahan, D. (2016).,
Anti-tax interacting protein-1 (TIP-1) monoclonal antibody targets human cancers., Oncotarget, 7(28), 43352-43362. doi:10.18632/oncotarget.9713 [doi]
Juzeniene, A., Bernoulli, J., Suominen, M., Halleen, J., & Larsen, R. H. (2018).,
Antitumor activity of novel bone-seeking, alpha-emitting (224)ra-solution in a breast cancer skeletal metastases model, Anticancer Research, 38(4), 1947-1955. doi:38/4/1947 [pii]
Brignole C, Calarco E, Bensa V, Giusto E, Perri P, Ciampi E, Corrias MV, Astigiano S, Cilli M, Loo D, Bonvini E, Pastorino F, Ponzoni M.,
Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma., J Immunother Cancer. 2023 Sep;11(9). pii: e007174. doi: 10.1136/jitc-2023-007174.
Ben-Eltriki M, Deb S, Shankar G, Meckling G, Hassona M, Yamazaki T, Fazli L, Chin MY, Tomlinson Guns ES.,
Anti-Tumor Effects of Ginsenoside 20(S)-Protopanaxadiol and 1,25-Dihydroxyvitamin D3 Combination in Castration Resistant Prostate Cancer, Medicines (Basel). 2021 Jun 4;8(6):28. doi: 10.3390/medicines8060028.
Hallin J, Bowcut V, Calinisan A, Briere DM, Hargis L, Engstrom LD, Laguer J, Medwid J, Vanderpool D, Lifset E, Trinh D, Hoffman N, Wang X, David Lawson J, Gunn RJ, Smith CR, Thomas NC, Martinson M, Bergstrom A, Sullivan F, Bouhana K, Winski S, He L, Fernandez-Banet J, Pavlicek A, Haling JR, Rahbaek L, Marx MA, Olson P, Christensen JG.,
Anti-tumor efficacy of a potent and selective non-covalent KRAS(G12D) inhibitor, Nat Med. 2022 Oct;28(10):2171-2182. doi: 10.1038/s41591-022-02007-7. Epub 2022 Oct 10.
Su W, Mukherjee R, Yaeger R, Son J, Xu J, Na N, Merna Timaul N, Hechtman J, Paroder V, Lin M, Mattar M, Qiu J, Chang Q, Zhao H, Zhang J, Little M, Adachi Y, Han SW, Taylor BS, Ebi H, Abdel-Wahab O, de Stanchina E, Rudin CM, Jänne PA, McCormick F, Yao Z, Rosen N.,
ARAF protein kinase activates RAS by antagonizing its binding to RASGAP NF1, Mol Cell. 2022 Jul 7;82(13):2443-2457.e7. doi: 10.1016/j.molcel.2022.04.034. Epub 2022 May 24.
Smith RA, Zammit DJ, Damle NK, Usansky H, Reddy SP, Lin JH, Mistry M, Rao NS, Denis LJ, Gupta S.,
ASN004, A 5T4-targeting scFv-Fc Antibody-Drug Conjugate with High Drug-to-Antibody Ratio, Induces Complete and Durable Tumor Regressions in Preclinical Models, Mol Cancer Ther. 2021 Aug;20(8):1327-1337. doi: 10.1158/1535-7163.MCT-20-0565. Epub 2021 May 27.
Zumwalt, T. J., Wodarz, D., Komarova, N. L., Toden, S., Turner, J., Cardenas, J., . . . Goel, A. (2017).,
Aspirin-induced chemoprevention and response kinetics are enhanced by PIK3CA mutations in colorectal cancer cells., Cancer Prevention Research (Philadelphia, Pa.), 10(3), 208-218. doi:10.1158/1940-6207.CAPR-16-0175 [doi]
Green, D. J., Shadman, M., Jones, J. C., Frayo, S. L., Kenoyer, A. L., Hylarides, M. D., . . . Press, O. W. (2015).,
Astatine-211 conjugated to an anti-CD20 monoclonal antibody eradicates disseminated B-cell lymphoma in a mouse model, Blood, 125(13), 2111-2119. doi:10.1182/blood-2014-11-612770 [doi]
Davis SL, Hartman SJ, Bagby SM, Schlaepfer M, Yacob BW, Tse T, Simmons DM, Diamond JR, Lieu CH, Leal AD, Cadogan EB, Hughes GD, Durant ST, Messersmith WA, Pitts TM.,
ATM kinase inhibitor AZD0156 in combination with irinotecan and 5-fluorouracil in preclinical models of colorectal cancer, BMC Cancer. 2022 Oct 29;22(1):1107. doi: 10.1186/s12885-022-10084-7.
Di Francesco M, Pastorino F, Ferreira M, Fragassi A, Di Francesco V, Palange AL, Celia C, Di Marzio L, Cilli M, Bensa V, Ponzoni M, Decuzzi P.,
Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma, Pharmacol Res. 2022 Dec 28;188:106639. doi: 10.1016/j.phrs.2022.106639. Online ahead of print.
Di Francesco M, Pastorino F, Ferreira M, Fragassi A, Di Francesco V, Palange AL, Celia C, Di Marzio L, Cilli M, Bensa V, Ponzoni M, Decuzzi P.,
Augmented efficacy of nano-formulated docetaxel plus curcumin in orthotopic models of neuroblastoma., Pharmacol Res. 2023 Feb;188:106639. doi: 10.1016/j.phrs.2022.106639. Epub 2022 Dec 28.
Johnson SS, Liu D, Ewald JT, Robles-Planells C, Bayanbold K, Wels BR, Solst SR, O'Dorisio MS, Allen BG, Menda Y, Spitz DR, Fath MA.,
Auranofin Inhibition of Thioredoxin Reductase in a Preclinical Model of Small Cell Lung Cancer., bioRxiv. 2023 May 9. pii: 2023.05.07.539772. doi: 10.1101/2023.05.07.539772.
Yeo, S. K., Wen, J., Chen, S., & Guan, J. L. (2016).,
Autophagy differentially regulates distinct breast cancer stem-like cells in murine models via EGFR/Stat3 and Tgfbeta/Smad signaling, Cancer Research, 76(11), 3397-3410. doi:10.1158/0008-5472.CAN-15-2946 [doi]
Wang Y, Xie W, Humeau J, Chen G, Liu P, Pol J, Zhang Z, Kepp O, Kroemer G.,
Autophagy induction by thiostrepton improves the efficacy of immunogenic chemotherapy, J Immunother Cancer. 2020 Mar;8(1):e000462. doi: 10.1136/jitc-2019-000462.
Loddick, S. A., Ross, S. J., Thomason, A. G., Robinson, D. M., Walker, G. E., Dunkley, T. P., . . . Brooks, A. N. (2013).,
AZD3514: A small molecule that modulates androgen receptor signaling and function in vitro and in vivo., Molecular Cancer Therapeutics, 12(9), 1715-1727. doi:10.1158/1535-7163.MCT-12-1174 [doi]
Fok, Jacqueline H L; Ramos-Montoya, Antonio; Vazquez-Chantada, Mercedes; Wijnhoven, Paul W G; Follia, Valeria; James, Neil; Farrington, Paul M; Karmokar, Ankur; Willis, Sophie E; Cairns, Jonathan; Nikkilä, Jenni; Beattie, David; Lamont, Gillian M; Finlay, M Raymond V; Wilson, Joanne; Smith, Aaron; OConnor, Lenka Oplustil; Ling, Stephanie; Fawell, Stephen E; OConnor, Mark J; Hollingsworth, Simon J; Dean, Emma; Goldberg, Frederick W; Davies, Barry R; Cadogan, Elaine B;,
AZD7648 is a potent and selective DNA-PK inhibitor that enhances radiation, chemotherapy and olaparib activity., Nature communications Vol.10, 2019
Rello-Varona, Santi; Fuentes-Guirado, Miriam; LĂłpez-Alemany, Roser; Contreras-PĂŠrez, Aida; Mulet-Margalef, NĂşria; GarcĂa-MonclĂşs, Silvia; Tirado, Oscar M; GarcĂa Del Muro, Xavier,
Bcl-xL inhibition enhances Dinaciclib-induced cell death in soft-tissue sarcomas, Scientific reports Vol.9, 2019
San Millan, C., Soldevilla, B., Martin, P., Gil-Calderon, B., Compte, M., Perez-Sacristan, B., . . . Dominguez, G. (2015),
Beta-cryptoxanthin synergistically enhances the antitumoral activity of oxaliplatin through DeltaNP73 negative regulation in colon cancer, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(19), 4398-4409. doi:10.1158/1078-0432.CCR-14-2027 [doi]
Jansen, M. H., Lagerweij, T., Sewing, A. C., Vugts, D. J., van Vuurden, D. G., Molthoff, C. F., . . . Hulleman, E. (2016).,
Bevacizumab targeting diffuse intrinsic pontine glioma: Results of 89Zr-bevacizumab PET imaging in brain tumor models., Molecular Cancer Therapeutics, 15(9), 2166-2174. doi:10.1158/1535-7163.MCT-15-0558 [doi]
Singh AK, Dadey DY, Rau MJ, Fitzpatrick J, Shah HK, Saikia M, Townsend R, Thotala D, Hallahan DE, Kapoor V.,
Blocking the functional domain of TIP1 by antibodies sensitizes cancer to radiation therapy., Biomed Pharmacother. 2023 Oct;166:115341. doi: 10.1016/j.biopha.2023.115341. Epub 2023 Aug 23.
Zhang, Y., Chen, X., Qiao, M., Zhang, B. Q., Wang, N., Zhang, Z., . . . Zhang, H. (2014).,
Bone morphogenetic protein 2 inhibits the proliferation and growth of human colorectal cancer cells., Oncology Reports, 32(3), 1013-1020. doi:10.3892/or.2014.3308 [doi]
Bai L, Li X, Yang Y, Zhao R, White EZ, Danaher A, Bowen NJ, Hinton CV, Cook N, Li D, Wu AY, Qui M, Du Y, Fu H, Kucuk O, Wu D.,
Bromocriptine monotherapy overcomes prostate cancer chemoresistance in preclinical models., Transl Oncol. 2023 Aug;34:101707. doi: 10.1016/j.tranon.2023.101707. Epub 2023 Jun 2.
Patel N, Kommineni N, Surapaneni SK, Kalvala A, Yaun X, Gebeyehu A, Arthur P, Duke LC, York SB, Bagde A, Meckes DG Jr, Singh M.,
Cannabidiol loaded extracellular vesicles sensitize triple-negative breast cancer to doxorubicin in both in-vitro and in vivo models, Int J Pharm. 2021 Sep 25;607:120943. doi: 10.1016/j.ijpharm.2021.120943. Epub 2021 Jul 27.
Bort, A., Spinola, E., Rodriguez-Henche, N., & Diaz-Laviada, I. (2017).,
Capsaicin exerts synergistic antitumor effect with sorafenib in hepatocellular carcinoma cells through AMPK activation, Oncotarget, 8(50), 87684-87698. doi:10.18632/oncotarget.21196 [doi]
Kim, H. S., Masko, E. M., Poulton, S. L., Kennedy, K. M., Pizzo, S. V., Dewhirst, M. W., & Freedland, S. J. (2012).,
Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer., BJU International, 110(7), 1062-1069. doi:10.1111/j.1464-410X.2012.10971.x [doi]
Li, H., Xie, N., Gleave, M. E., & Dong, X. (2015,
Catalytic inhibitors of DNA topoisomerase II suppress the androgen receptor signaling and prostate cancer progression., Oncotarget, 6(24), 20474-20484. doi:4105 [pii]
Assimon, Victoria A; Tang, Yangzhong; Vargas, Jesse D; Lee, Grace J; Wu, Zhi Yong; Lou, Kenny; Yao, Bing; Menon, Mary-Kamala; Pios, Ariel; Perez, Kristy C; Madriaga, Antonett; Buchowiecki, Peter K; Rolfe, Mark; Shawver, Laura; Jiao, Xianyun; Le Moigne, Ronan; Zhou, Han-Jie; Anderson, Daniel J;,
CB-6644 Is a Selective Inhibitor of the RUVBL1/2 Complex with Anticancer Activity. ACS chemical biology, ACS chemical biology Vol.14, 2019
Domínguez JM, Pérez-Chacón G, Guillén MJ, Muñoz-Alonso MJ, Somovilla-Crespo B, Cibrián D, Acosta-Iborra B, Adrados M, Muñoz-Calleja C, Cuevas C, Sánchez-Madrid F, Avilés P, Zapata JM.,
CD13 as a new tumor target for antibody-drug conjugates: validation with the conjugate MI130110, J Hematol Oncol. 2020 Apr 7;13(1):32. doi: 10.1186/s13045-020-00865-7.
Puigdelloses M, Garcia-Moure M, Labiano S, Laspidea V, Gonzalez-Huarriz M, Zalacain M, Marrodan L, Martinez-Velez N, De la Nava D, Ausejo I, Hervás-Stubbs S, Herrador G, Chen Z, Hambardzumyan D, Patino Garcia A, Jiang H, Gomez-Manzano C, Fueyo J, Gállego Pérez-Larraya J, Alonso M.,
CD137 and PD-L1 targeting with immunovirotherapy induces a potent and durable antitumor immune response in glioblastoma models, J Immunother Cancer. 2021 Jul;9(7):e002644. doi: 10.1136/jitc-2021-002644.
Hernandez, R., Sun, H., England, C. G., Valdovinos, H. F., Ehlerding, E. B., Barnhart, T. E., . . . Cai, W. (2016),
CD146-targeted immunoPET and NIRF imaging of hepatocellular carcinoma with a dual-labeled monoclonal antibody., Theranostics, 6(11), 1918-1933. doi:10.7150/thno.15568 [doi]
Smith, M. C., Mader, M. M., Cook, J. A., Iversen, P., Ajamie, R., Perkins, E., . . . Wacheck, V. (2016).,
Characterization of LY3023414, a novel PI3K/mTOR dual inhibitor eliciting transient target modulation to impede tumor growth., Molecular Cancer Therapeutics, 15(10), 2344-2356. doi:1535-7163.MCT-15-0996 [pii]
Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, Kauffmann A, Guthy D, Erdmann D, De Pover A, Furet P, Gao H, Ferretti S, Wang Y, Trappe J, Brachmann SM, Maira SM, Wilson C, Boehm M, Garcia-Echeverria C, Chene P, Wiesmann M, Cozens R, Lehar J, Schlegel R, Caravatti G, Hofmann F, Sellers WR.,
Characterization of the novel and specific PI3K? inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials, Mol Cancer Ther. 2014 May;13(5):1117-29. doi: 10.1158/1535-7163.MCT-13-0865. Epub 2014 Mar 7.
Bolaender A, Zatorska D, He H, Joshi S, Sharma S, Digwal CS, Patel HJ, Sun W, Imber BS, Ochiana SO, Patel MR, Shrestha L, Shah SK, Wang S, Karimov R, Tao H, Patel PD, Martin AR, Yan P, Panchal P, Almodovar J, Corben A, Rimner A, Ginsberg SD, Lyashchenko S, Burnazi E, Ku A, Kalidindi T, Lee SG, Grkovski M, Beattie BJ, Zanzonico P, Lewis JS, Larson S, Rodina A, Pillarsetty N, Tabar V, Dunphy MP, Taldone T, Shimizu F, Chiosis G.,
Chemical tools for epichaperome-mediated interactome dysfunctions of the central nervous system, Nat Commun. 2021 Aug 3;12(1):4669. doi: 10.1038/s41467-021-24821-2.
Weitzenfeld, P., Kossover, O., Korner, C., Meshel, T., Wiemann, S., Seliktar, D., . . . Ben-Baruch, A. (2016).,
Chemokine axes in breast cancer: Factors of the tumor microenvironment reshape the CCR7-driven metastatic spread of luminal-A breast tumors., Journal of Leukocyte Biology, 99(6), 1009-1025. doi:10.1189/jlb.3MA0815-373R [doi]
Russo M, Panini N, Fabbrizio P, Formenti L, Becchetti R, Matteo C, Meroni M, Nastasi C, Cappelleri A, Frapolli R, Nardo G, Scanziani E, Ponzetta A, Bani MR, Ghilardi C, Giavazzi R.,
Chemotherapy-induced neutropenia elicits metastasis formation in mice by promoting proliferation of disseminated tumor cells., Oncoimmunology. 2023 Aug 1;12(1):2239035. doi: 10.1080/2162402X.2023.2239035. eCollection 2023.
Sen, T., Tong, P., Stewart, C. A., Cristea, S., Valliani, A., Shames, D. S., . . . Byers, L. A. (2017).,
CHK1 inhibition in small-cell lung cancer produces single-agent activity in biomarker-defined disease subsets and combination activity with cisplatin or olaparib., Cancer Research, 77(14), 3870-3884. doi:10.1158/0008-5472.CAN-16-3409 [doi]
Li, J., Qu, X., Tian, J., Zhang, J. T., & Cheng, J. X. (2018).,
Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation., PloS One, 13(2), e0193318. doi:10.1371/journal.pone.0193318 [doi]
Sobot, D., Mura, S., Rouquette, M., Vukosavljevic, B., Cayre, F., Buchy, E., . . . Couvreur, P. (2017).,
Circulating lipoproteins: A trojan horse guiding squalenoylated drugs to LDL-accumulating cancer cells., Molecular Therapy : The Journal of the American Society of Gene Therapy, 25(7), 1596-1605. doi:S1525-0016(17)30234-4 [pii]
Yu, W., Chen, Y., Dubrulle, J., Stossi, F., Putluri, V., Sreekumar, A., . . . Sandulache, V. C. (2018).,
Cisplatin generates oxidative stress which is accompanied by rapid shifts in central carbon metabolism, Scientific Reports, 8(1), 4306-018-22640-y. doi:10.1038/s41598-018-22640-y [doi]
Tornan J, Mateu-Sanz M, Rey V, Murillo D, Huergo C, Gallego B, RodrÃguez A, RodrÃguez R, Canal C.,
Cold plasma and inhibition of STAT3 selectively target tumorigenicity in osteosarcoma., Redox Biol. 2023 Jun;62:102685. doi: 10.1016/j.redox.2023.102685. Epub 2023 Mar 20.
Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.,
Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer, Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Online ahead of print.
Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.,
Combinatorial Efficacy of Olaparib with Radiation and ATR Inhibitor Requires PARP1 Protein in Homologous Recombination-Proficient Pancreatic Cancer, Mol Cancer Ther. 2021 Feb;20(2):263-273. doi: 10.1158/1535-7163.MCT-20-0365. Epub 2020 Dec 2.
Belli, Valentina; Matrone, Nunzia; Napolitano, Stefania; Migliardi, Giorgia; Cottino, Francesca; Bertotti, Andrea; Trusolino, Livio; Martinelli, Erika; Morgillo, Floriana; Ciardiello, Davide; De Falco, Vincenzo; Giunta, Emilio Francesco; Bracale, Umberto; Ciardiello, Fortunato; Troiani, Teresa;,
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models., Journal of experimental & clinical cancer research : CR Vol.38, 2019
Frost, S. H., Frayo, S. L., Miller, B. W., Orozco, J. J., Booth, G. C., Hylarides, M. D., . . . Press, O. W. (2015),
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models., PloS One, 10(3), e0120561. doi:10.1371/journal.pone.0120561 [doi]
Vugts, D. J., Klaver, C., Sewing, C., Poot, A. J., Adamzek, K., Huegli, S., . . . van Dongen, G. A. (2017).,
Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for (89)zr-immuno-PET., European Journal of Nuclear Medicine and Molecular Imaging, 44(2), 286-295. doi:10.1007/s00259-016-3499-x [doi]
Pattarawat P, Hong T, Wallace S, Hu Y, Donnell R, Wang TH, Tsai CL, Wang J, Wang HR.,
Compensatory combination of romidepsin with gemcitabine and cisplatin to effectively and safely control urothelial carcinoma, Br J Cancer. 2020 Jul;123(2):226-239. doi: 10.1038/s41416-020-0877-8. Epub 2020 May 11.
Shibata M, Ooki A, Inokawa Y, Sadhukhan P, Ugurlu MT, Izumchenko E, Munari E, Bogina G, Rudin CM, Gabrielson E, Singh A, Hoque MO.,
Concurrent Targeting of Potential Cancer Stem Cells Regulating Pathways Sensitizes Lung Adenocarcinoma to Standard Chemotherapy, Mol Cancer Ther. 2020 Oct;19(10):2175-2185. doi: 10.1158/1535-7163.MCT-20-0024. Epub 2020 Aug 26.
Restifo D, McDermott JR, Cvetkovic D, Dos Santos T, Ogier C, Surumbayeva A, Handorf EA, Schimke C, Ma C, Cai KQ, Olszanski AJ, Kathad U, Bhatia K, Sharma P, Kulkarni A, Astsaturov I.,
Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies., Mol Cancer Ther. 2023 Oct 2;22(10):1182-1190. doi: 10.1158/1535-7163.MCT-22-0818.
Patel SS, Hoogenboezem EN, Yu F, DeJulius CR, Fletcher RB, Sorets AG, Cherry FK, Lo JH, Bezold MG, Francini N, d'Arcy R, Brasuell JE, Cook RS, Duvall CL.,
Core polymer optimization of ternary siRNA nanoparticles enhances in vivo safety, pharmacokinetics, and tumor gene silencing., Biomaterials. 2023 Jun;297:122098. doi: 10.1016/j.biomaterials.2023.122098. Epub 2023 Mar 28.
Liu, Peng; Zhao, Liwei; Pol, Jonathan; Levesque, Sarah; Petrazzuolo, Adriana; Pfirschke, Christina; Engblom, Camilla; Rickelt, Steffen; Yamazaki, Takahiro; Iribarren, Kristina; Senovilla, Laura; Bezu, Lucillia; Vacchelli, Erika; Sica, Valentina; Melis, AndrÊa; Martin, Tiffany; Xia, Lin; Yang, Heng; Li, Qingqing; Chen, Jinfeng; Durand, Sylvère; Aprahamian, Fanny; Lefevre, Deborah; Broutin, Sophie; Paci, Angelo; Bongers, Amaury; Minard-Colin, Veronique; Tartour, Eric; Zitvogel, Laurence; Apetoh, Lionel; Ma, Yuting; Pittet, Mikael J; Kepp, Oliver; Kroemer, Guido;,
Crizotinib-induced immunogenic cell death in non-small cell lung cancer, Nature communications Vol.10, 2019
Grand-Guillaume J, Mansi R, Gaonkar RH, Zanger S, Fani M, Eugster PJ, Beck Popovic M, Grouzmann E, Abid K.,
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake ((123/131)I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumors., J Transl Med. 2023 Sep 7;21(1):604. doi: 10.1186/s12967-023-04466-z.
Yamaguchi, M., Zhu, S., Zhang, S., Wu, D., Moore, T. M., Snyder, J. P., & Shoji, M. (2014).,
Curcumin analogue UBS109 prevents bone loss in breast cancer bone metastasis mouse model: Involvement in osteoblastogenesis and osteoclastogenesis, Cell and Tissue Research, 357(1), 245-252. doi:10.1007/s00441-014-1846-4 [doi]
Domanska, U. M., Boer, J. C., Timmer-Bosscha, H., van Vugt, M. A., Hoving, H. D., Kliphuis, N. M., . . . Walenkamp, A. M. (2014).,
CXCR4 inhibition enhances radiosensitivity, while inducing cancer cell mobilization in a prostate cancer mouse model, Clinical & Experimental Metastasis, 31(7), 829-839. doi:10.1007/s10585-014-9673-2 [doi]
Garcia, M., Velez, R., Romagosa, C., Majem, B., Pedrola, N., Olivan, M., . . . Doll, A. (2014).,
Cyclooxygenase-2 inhibitor suppresses tumour progression of prostate cancer bone metastases in nude mice, BJU International, 113(5b), E164-77. doi:10.1111/bju.12503 [doi]
Kapoor S, Gustafson T, Zhang M, Chen YS, Li J, Nguyen N, Perez JET, Dashwood WM, Rajendran P, Dashwood RH.,
Deacetylase Plus Bromodomain Inhibition Downregulates ERCC2 and Suppresses the Growth of Metastatic Colon Cancer Cells, Cancers (Basel). 2021 Mar 22;13(6):1438. doi: 10.3390/cancers13061438.
McCarthy GA, Di Niro R, Finan JM, Jain A, Guo Y, Wyatt CR, Guimaraes AR, Waugh TA, Keith D, Morgan TK, Sears RC, Brody JR.,
Deletion of the mRNA stability factor ELAVL1 (HuR) in pancreatic cancer cells disrupts the tumor microenvironment integrity., NAR Cancer. 2023 Apr 19;5(2):zcad016. doi: 10.1093/narcan/zcad016. eCollection 2023 Jun.
Bayanbold K, Singhania M, Fath MA, Searby CC, Stolwijk JM, Henrich JB, Pulliam CF, Schoenfeld JD, Mapuskar KA, Sho S, Caster JM, Allen BG, Buettner GR, Spies M, Goswami PC, Petronek MS, Spitz DR.,
Depletion of Labile Iron Induces Replication Stress and Enhances Responses to Chemoradiation in Non-Small-Cell Lung Cancer., Antioxidants (Basel). 2023 Nov 15;12(11). pii: 2005. doi: 10.3390/antiox12112005.
Kinneer K, Wortmann P, Cooper ZA, Dickinson NJ, Masterson L, Cailleau T, Hutchinson I, Vijayakrishnan B, McFarlane M, Ball K, Davies M, Lewis A, Huang Y, Rosenbaum AI, Yuan J, Chesebrough J, Anderton J, Monks N, Novick S, Wang J, Dimasi N, Christie RJ, et al.,
Design and Preclinical Evaluation of a Novel B7-H4-Directed Antibody-Drug Conjugate, AZD8205, Alone and in Combination with the PARP1-Selective Inhibitor AZD5305., Clin Cancer Res. 2023 Mar 14;29(6):1086-1101. doi: 10.1158/1078-0432.CCR-22-2630.
Perez, O. D., Logg, C. R., Hiraoka, K., Diago, O., Burnett, R., Inagaki, A., . . . Jolly, D. J. (2012).,
Design and selection of toca 511 for clinical use: Modified retroviral replicating vector with improved stability and gene expression, Molecular Therapy : The Journal of the American Society of Gene Therapy, 20(9), 1689-1698. doi:10.1038/mt.2012.83 [doi]
Nordmaj MA, Roberts ME, Sachse ES, Dagil R, Andersen AP, Skeltved N, Grunddal KV, Erdoğan SM, Choudhary S, Gustsavsson T, Ørum-Madsen MS, Moskalev I, Tian W, Yang Z, Clausen TM, Theander TG, Daugaard M, Nielsen MA, Salanti A.,
Development of a bispecific immune engager using a recombinant malaria protein, Cell Death Dis. 2021 Apr 6;12(4):353. doi: 10.1038/s41419-021-03611-0.
Metwally K, Bastiancich C, Correard F, Novell A, Fernandez S, Guillet B, Larrat B, Mensah S, Estčve MA, Da Silva A.,
Development of a multi-functional preclinical device for the treatment of glioblastoma, Biomed Opt Express. 2021 Mar 23;12(4):2264-2279. doi: 10.1364/BOE.419412. eCollection 2021 Apr 1.
D'Hollander, A., Mathieu, E., Jans, H., Vande Velde, G., Stakenborg, T., Van Dorpe, P., . . . Lagae, L. (2016),
Development of nanostars as a biocompatible tumor contrast agent: Toward in vivo SERS imaging., International Journal of Nanomedicine, 11, 3703-3714. doi:10.2147/IJN.S91340 [doi]
Navarro-Villaran, E., Tinoco, J., Jimenez, G., Pereira, S., Wang, J., Aliseda, S., . . . Muntane, J. (2016).,
Differential antitumoral properties and renal-associated tissue damage induced by tacrolimus and mammalian target of rapamycin inhibitors in hepatocarcinoma: In vitro and in vivo studies, PloS One, 11(8), e0160979. doi:10.1371/journal.pone.0160979 [doi]
Oksala, R., Moilanen, A., Riikonen, R., Rummakko, P., Karjalainen, A., Passiniemi, M., . . . Mustonen, M. V. (2018),
Discovery and development of ODM-204: A novel nonsteroidal compound for the treatment of castration-resistant prostate cancer by blocking the androgen receptor and inhibiting CYP17A1, The Journal of Steroid Biochemistry and Molecular Biology, doi:S0960-0760(18)30078-5 [pii]
Toader D, Fessler SP, Collins SD, Conlon PR, Bollu R, Catcott KC, Chin CN, Dirksen A, Du B, Duvall JR, Higgins S, Kozytska MV, Bellovoda K, Faircloth C, Lee D, Li F, Qin L, Routhier C, Shaw P, Stevenson CA, Wang J, Wongthida P, et al.,
Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer., Mol Cancer Ther. 2023 Sep 5;22(9):999-1012. doi: 10.1158/1535-7163.MCT-22-0786.
Hiriyan, J., Shivarudraiah, P., Gavara, G., Annamalai, P., Natesan, S., Sambasivam, G., & Sukumaran, S. K. (2015).,
Discovery of PAT-1102, a novel, potent and orally active histone deacetylase inhibitor with antitumor activity in cancer mouse models. Anticancer, Anticancer Research, 35(1), 229-237. doi:35/1/229 [pii]
Donabedian, P. L., Kossatz, S., Engelbach, J. A., Jannetti, S. A., Carney, B., Young, R. J., . . . Reiner, T. (2018).,
Discriminating radiation injury from recurrent tumor with [(18)F]PARPi and amino acid PET in mouse models., EJNMMI Research, 8(1), 59-018-0399-z. doi:10.1186/s13550-018-0399-z [doi]
Tuomela, J., Sandholm, J., Kaakinen, M., Patel, A., Kauppila, J. H., Ilvesaro, J., . . . Selander, K. S. (2013).,
DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cells., Breast Cancer Research and Treatment, 142(3), 477-487. doi:10.1007/s10549-013-2762-0 [doi]
Laakso H, Ylä-Herttuala E, Sierra A, Jambor I, Poutanen M, Liljenbäck H, Virtanen H, Merisaari H, Aronen H, Minn H, Roivainen A, Liimatainen T.,
Docetaxel chemotherapy response in PC3 prostate cancer mouse model detected by rotating frame relaxations and water diffusion, NMR Biomed. 2021 Apr;34(4):e4483. doi: 10.1002/nbm.4483. Epub 2021 Feb 4.
Youngblood MW, Tran AN, Wang W, An S, Scholtens D, Zhang L, O'Shea K, Pokorny JL, Magill ST, Sachdev S, Lukas RV, Ahmed A, Unruh D, Walshon J, McCortney K, Wang Y, Baran A, Sahm F, Aldape K, Chandler JP, David James C, Heimberger AB, et al.,
Docetaxel targets aggressive methylation profiles and serves as a radiosensitizer in high-risk meningiomas., Neuro Oncol. 2023 Mar 14;25(3):508-519. doi: 10.1093/neuonc/noac206.
Sciegienka, S. J., Solst, S. R., Falls, K. C., Schoenfeld, J. D., Klinger, A. R., Ross, N. L., . . . Fath, M. A. (2017).,
D-penicillamine combined with inhibitors of hydroperoxide metabolism enhances lung and breast cancer cell responses to radiation and carboplatin via H2O2-mediated oxidative stress., Free Radical Biology & Medicine, 108, 354-361. doi:S0891-5849(17)30192-2 [pii]
Tsoneva, D., Stritzker, J., Bedenk, K., Zhang, Q., Frentzen, A., Cappello, J., . . . Szalay, A. A. (2015).,
Drug-encoded biomarkers for monitoring biological therapies, PloS One, 10(9), e0137573. doi:10.1371/journal.pone.0137573 [doi]
Ohana, J., Sandler, U., Kass, G., Stemmer, S. M., & Devary, Y. (2017).,
dTCApFs, a derivative of a novel human hormone peptide, induces apoptosis in cancer cells through a mechanism involving loss of golgi function., Molecular and Clinical Oncology, 7(6), 991-999. doi:10.3892/mco.2017.1453 [doi]
Kostecki KL, Iida M, Wiley AL, Kimani S, Mehall B, Tetreault K, Alexandridis R, Yu M, Hong S, Salgia R, Bruce JY, Birge RB, Harari PM, Wheeler DL.,
Dual Axl/MerTK inhibitor INCB081776 creates a proinflammatory tumor immune microenvironment and enhances anti-PDL1 efficacy in head and neck cancer., Head Neck. 2023 May;45(5):1255-1271. doi: 10.1002/hed.27340. Epub 2023 Mar 20.
Luo, H., England, C. G., Shi, S., Graves, S. A., Hernandez, R., Liu, B., . . . Cai, W. (2016).,
Dual targeting of tissue factor and CD105 for preclinical PET imaging of pancreatic cancer., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(15), 3821-3830. doi:10.1158/1078-0432.CCR-15-2054 [doi]
Kleczko EK, Hinz TK, Nguyen TT, Gurule NJ, Navarro A, Le AT, Johnson AM, Kwak J, Polhac DI, Clambey ET, Weiser-Evans M, Merrick DT, Yang MC, Patil T, Schenk EL, Heasley LE, Nemenoff RA.,
Durable responses to alectinib in murine models of EML4-ALK lung cancer requires adaptive immunity., NPJ Precis Oncol. 2023 Feb 4;7(1):15. doi: 10.1038/s41698-023-00355-2.
Tan, Q., Joshua, A. M., Saggar, J. K., Yu, M., Wang, M., Kanga, N., . . . Tannock, I. F. (2015),
Effect of pantoprazole to enhance activity of docetaxel against human tumour xenografts by inhibiting autophagy., British Journal of Cancer, 112(5), 832-840. doi:10.1038/bjc.2015.17 [doi]
Ionkina, A. A., Tentler, J. J., Kim, J., Capasso, A., Pitts, T. M., Ryall, K. A., . . . Diamond, J. R. (2017).,
Efficacy and molecular mechanisms of differentiated response to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical models of p53-mutated triple-negative breast cancer., Frontiers in Oncology, 7, 94. doi:10.3389/fonc.2017.00094 [doi]
Kong, Y., Barisone, G. A., Sidhu, R. S., O'Donnell, R. T., & Tuscano, J. M. (2015).,
Efficacy of combined histone deacetylase and checkpoint kinase inhibition in a preclinical model of human burkitt lymphoma., Molecular Medicine (Cambridge, Mass.), 21(1), 824-832. doi:10.2119/molmed.2015.00032 [doi]
Akla, Barbara; Broussas, Matthieu; Loukili, Noureddine; Robert, Alain; Beau-Larvor, Charlotte; Malissard, Martine; Boute, Nicolas; Champion, Thierry; Haeuw, Jean-Francois; Beck, Alain; Perez, Michel; Dreyfus, Cyrille; Pavlyuk, Mariya; Chetaille, Eric; Corvaia, Nathalie;,
Efficacy of the Antibody-Drug Conjugate W0101 in Preclinical Models of IGF-1 Receptor Overexpressing Solid Tumors., Molecular cancer therapeutics Vol.19, 2020
Kang J, Chun J, Hwang JS, Pan C, Li J, Boese AC, Young I, Malin CM, Kang Y, Gibbons DL, Sica G, Fu H, Ramalingam SS, Jin L, Kang S.,
EGFR-phosphorylated GDH1 harmonizes with RSK2 to drive CREB activation and tumor metastasis in EGFR-activated lung cancer, Cell Rep. 2022 Dec 13;41(11):111827. doi: 10.1016/j.celrep.2022.111827.
Zalles M, Smith N, Saunders D, Guzman M, Lerner M, Fung KM, Babu A, Battiste J, Chung J, Hwang K, Jin J, Towner RA.,
ELTD1 as a multi-focal target for malignant gliomas: preclinical studies, Neurooncol Adv. 2021 Sep 17;3(1):vdab132. doi: 10.1093/noajnl/vdab132. eCollection 2021 Jan-Dec.
Choi, A. H., O'Leary, M. P., Lu, J., Kim, S. I., Fong, Y., & Chen, N. G. (2018),
Endogenous akt activity promotes virus entry and predicts efficacy of novel chimeric orthopoxvirus in triple-negative breast cancer., Molecular Therapy Oncolytics, 9, 22-29. doi:10.1016/j.omto.2018.04.001 [doi]
Sancho-Albero M, Facchetti G, Panini N, Meroni M, Bello E, Rimoldi I, Zucchetti M, Frapolli R, De Cola L.,
Enhancing Pt(IV) Complexes' Anticancer Activity upon Encapsulation in Stimuli-Responsive Nanocages., Adv Healthc Mater. 2023 Jul;12(17):e2202932. doi: 10.1002/adhm.202202932. Epub 2023 Mar 28.
Siddique HR, Liao DJ, Mishra SK, Schuster T, Wang L, Matter B, Campbell PM, Villalta P, Nanda S, Deng Y, Saleem M.,
Epicatechin-rich cocoa polyphenol inhibits Kras-activated pancreatic ductal carcinoma cell growth in vitro and in a mouse model, Int J Cancer. 2012 Oct 1;131(7):1720-31. doi: 10.1002/ijc.27409. Epub 2012 Feb 18.
Toden, S., Tran, H. M., Tovar-Camargo, O. A., Okugawa, Y., & Goel, A. (2016),
Epigallocatechin-3-gallate targets cancer stem-like cells and enhances 5-fluorouracil chemosensitivity in colorectal cancer., Oncotarget, 7(13), 16158-16171. doi:10.18632/oncotarget.7567 [doi]
Wang, X., Tan, Y., Cao, X., Kim, J. A., Chen, T., Hu, Y., . . . Wang, X. (2018).,
Epigenetic activation of HORMAD1 in basal-like breast cancer: Role in rucaparib sensitivity., Oncotarget, 9(53), 30115-30127. doi:10.18632/oncotarget.25728 [doi]
Evans JS, Beaumont J, Braga M, Masrour N, Mauri F, Beckley A, Butt S, Karali CS, Cawthorne C, Archibald S, Aboagye EO, Sharma R.,
Epigenetic potentiation of somatostatin-2 by guadecitabine in neuroendocrine neoplasias as a novel method to allow delivery of peptide receptor radiotherapy, Eur J Cancer. 2022 Nov;176:110-120. doi: 10.1016/j.ejca.2022.09.009. Epub 2022 Oct 5.
Jauhiainen S, Ilmonen H, Vuola P, Rasinkangas H, Pulkkinen HH, Keränen S, Kiema M, Liikkanen JJ, Laham-Karam N, Laidinen S, Beter M, Aavik E, Lappalainen K, Lohi J, Aronniemi J, Örd T, Kaikkonen MU, Salminen P, Tukiainen E, Ylä-Herttuala S, Laakkonen JP.,
ErbB signaling is a potential therapeutic target for vascular lesions with fibrous component., Elife. 2023 May 18;12. pii: e82543. doi: 10.7554/eLife.82543.
Schmitt, D. C., Madeira da Silva, L., Zhang, W., Liu, Z., Arora, R., Lim, S., . . . Tan, M. (2015).,
ErbB2-intronic microRNA-4728: A novel tumor suppressor and antagonist of oncogenic MAPK signaling., Cell Death & Disease, 6, e1742. doi:10.1038/cddis.2015.116 [doi]
Bhagwat SV, McMillen WT, Cai S, Zhao B, Whitesell M, Shen W, Kindler L, Flack RS, Wu W, Anderson B, Zhai Y, Yuan XJ, Pogue M, Van Horn RD, Rao X, McCann D, Dropsey AJ, Manro J, Walgren J, Yuen E, Rodriguez MJ, Plowman GD, Tiu RV, Joseph S, Peng SB.,
ERK Inhibitor LY3214996 Targets ERK Pathway-Driven Cancers: A Therapeutic Approach Toward Precision Medicine, Mol Cancer Ther. 2020 Feb;19(2):325-336. doi: 10.1158/1535-7163.MCT-19-0183. Epub 2019 Nov 19.
Maaland, Astri Fjelde; Heyerdahl, Helen; OShea, Adam; Eiriksdottir, Bergthora; Pascal, VĂŠronique; Andersen, Jan Terje; Kolstad, Arne; Dahle, Jostein;,
European journal of nuclear medicine and molecular imaging Vol.46, 2019, European journal of nuclear medicine and molecular imaging Vol.46, 2019
Tuominen S, Keller T, Petruk N, LĂłpez-PicĂłn F, Eichin D, LĂśyttyniemi E, Verhassel A, Rajander J, Sandholm J, Tuomela J, GrĂśnroos TJ.,
Evaluation of [(18)F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy, Eur J Nucl Med Mol Imaging. 2020 Dec 19. doi: 10.1007/s00259-020-05115-z. Online ahead of print.
Tuominen S, Keller T, Petruk N, López-Picón F, Eichin D, Löyttyniemi E, Verhassel A, Rajander J, Sandholm J, Tuomela J, Grönroos TJ.,
Evaluation of [(18)F]F-DPA as a target for TSPO in head and neck cancer under normal conditions and after radiotherapy, Eur J Nucl Med Mol Imaging. 2021 May;48(5):1312-1326. doi: 10.1007/s00259-020-05115-z. Epub 2020 Dec 19.
Scott, A. J., Song, E. K., Bagby, S., Purkey, A., McCarter, M., Gajdos, C., . . . Messersmith, W. A. (2017).,
Evaluation of the efficacy of dasatinib, a Src/Abl inhibitor, in colorectal cancer cell lines and explant mouse model., PloS One, 12(11), e0187173. doi:10.1371/journal.pone.0187173 [doi]
Scutigliani EM, Liang Y, IJff M, Rodermond H, Mei X, Korver MP, Orie VS, Hoebe RA, Picavet DI, Oei A, Kanaar R, Krawczyk PM.,
Evaluation of the Heat Shock Protein 90 Inhibitor Ganetespib as a Sensitizer to Hyperthermia-Based Cancer Treatments, Cancers (Basel). 2022 Oct 26;14(21):5250. doi: 10.3390/cancers14215250.
Siddiqui, I. A., Bharali, D. J., Nihal, M., Adhami, V. M., Khan, N., Chamcheu, J. C., . . . Mukhtar, H. (2014).,
Excellent anti-proliferative and pro-apoptotic effects of (-)-epigallocatechin-3-gallate encapsulated in chitosan nanoparticles on human melanoma cell growth both in vitro and in vivo., Nanomedicine : Nanotechnology, Biology, and Medicine, 10(8), 1619-1626. doi:10.1016/j.nano.2014.05.007 [doi]
Gonzalez-Sanchez L, Cobos-Fernandez MA, Lopez-Nieva P, Villa-Morales M, Stamatakis K, Cuezva JM, Marin-Rubio JL, Vazquez-Dominguez I, Gonzalez-Vasconcellos I, Salido E, Llamas P, Lopez-Lorenzo JL, Santos J, Fernandez-Piqueras J.,
Exploiting the passenger ACO1-deficiency arising from 9p21 deletions to kill T-cell lymphoblastic neoplasia cells, Carcinogenesis. 2020 Aug 12;41(8):1113-1122. doi: 10.1093/carcin/bgz185.
Sperger JM, Helzer KT, Stahlfeld CN, Jiang D, Singh A, Kaufmann KR, Niles DJ, Heninger E, Rydzewski NR, Wang L, Wang L, Yang R, Ren Y, Engle JW, Huang P, Kyriakopoulos CE, Slovin SF, Soule HR, Zhao SG, Kohli M, Tagawa ST, Cai W, et al.,
Expression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer., Clin Cancer Res. 2023 Jun 13;29(12):2324-2335. doi: 10.1158/1078-0432.CCR-22-1305.
Bownes LV, Williams AP, Marayati R, Stafman LL, Markert H, Quinn CH, Wadhwani N, Aye JM, Stewart JE, Yoon KJ, Mroczek-Musulman E, Beierle EA.,
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth, PLoS One. 2021 Mar 9;16(3):e0246244. doi: 10.1371/journal.pone.0246244. eCollection 2021.
Bownes LV, Williams AP, Marayati R, Stafman LL, Markert H, Quinn CH, Wadhwani N, Aye JM, Stewart JE, Yoon KJ, Mroczek-Musulman E, Beierle EA.,
EZH2 inhibition decreases neuroblastoma proliferation and in vivo tumor growth, PLoS One. 2021 Mar 9;16(3):e0246244. doi: 10.1371/journal.pone.0246244. eCollection 2021.
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C.,
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells, Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23.
Shen JZ, Qiu Z, Wu Q, Finlay D, Garcia G, Sun D, Rantala J, Barshop W, Hope JL, Gimple RC, Sangfelt O, Bradley LM, Wohlschlegel J, Rich JN, Spruck C.,
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells, Cell. 2021 Jan 21;184(2):352-369.e23. doi: 10.1016/j.cell.2020.11.042. Epub 2020 Dec 23.
Hicks HM, Pozdeyev N, Sams SB, Pugazhenthi U, Bales ES, Hofmann MC, McKenna LR, Schweppe RE.,
Fibronectin Contributes to a BRAF Inhibitor-driven Invasive Phenotype in Thyroid Cancer through EGR1, Which Can Be Blocked by Inhibition of ERK1/2., Mol Cancer Res. 2023 Sep 1;21(9):867-880. doi: 10.1158/1541-7786.MCR-22-1031.
Capasso, Anna; Bagby, Stacey M; Dailey, Kyrie L; Currimjee, Naomi; Yacob, Betelehem W; Ionkina, Anastasia; Frank, Julie G; Kim, Deog Joong; George, Christina; Lee, Young B; Benaim, Ely; Gittleman, Brian; Hartman, Sarah J; Tan, Aik Choon; Kim, Jihye; Pitts, Todd M; Eckhardt, S Gail; Tentler, John J; Diamond, Jennifer R;,
First-in-Class Phosphorylated-p68 Inhibitor RX-5902 Inhibits ??-Catenin Signaling and Demonstrates Antitumor Activity in Triple-Negative Breast Cancer, Molecular cancer therapeutics Vol.18, 2019
Faugeroux V, Pailler E, Oulhen M, Deas O, Brulle-Soumare L, Hervieu C, Marty V, Alexandrova K, Andree KC, Stoecklein NH, Tramalloni D, Cairo S, NgoCamus M, Nicotra C, Terstappen LWMM, Manaresi N, Lapierre V, Fizazi K, Scoazec JY, Loriot Y, Judde JG, Farace F.,
Genetic characterization of a unique neuroendocrine transdifferentiation prostate circulating tumor cell-derived eXplant model, Nat Commun. 2020 Apr 20;11(1):1884. doi: 10.1038/s41467-020-15426-2.
Sasaki, K., Kurahara, H., Young, E. D., Natsugoe, S., Ijichi, A., Iwakuma, T., & Welch, D. R. (2017).,
Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer., Clinical & Experimental Metastasis, 34(3-4), 229-239. doi:10.1007/s10585-017-9840-3 [doi]
Lampa, M., Arlt, H., He, T., Ospina, B., Reeves, J., Zhang, B., . . . Srinivasan, L. (2017).,
Glutaminase is essential for the growth of triple-negative breast cancer cells with a deregulated glutamine metabolism pathway and its suppression synergizes with mTOR inhibition, PloS One, 12(9), e0185092. doi:10.1371/journal.pone.0185092 [doi]
Sharp PS, Stylianou M, Arellano LM, Neves JC, Gravagnuolo AM, Dodd A, Barr K, Lozano N, Kisby T, Kostarelos K.,
Graphene Oxide Nanoscale Platform Enhances the Anti-Cancer Properties of Bortezomib in Glioblastoma Models, Adv Healthc Mater. 2023 Jan;12(3):e2201968. doi: 10.1002/adhm.202201968. Epub 2022 Nov 11.
Sorin, V., Ohana, P., Gallula, J., Birman, T., Matouk, I., Hubert, A., . . . Czerniak, A. (2012).,
H19-promoter-targeted therapy combined with gemcitabine in the treatment of pancreatic cancer, ISRN Oncology, 2012, 351750. doi:10.5402/2012/351750 [doi]
Zhou, Y., Li, G., Zhu, L., Li, C., Cornelius, L. A., & Wang, L. V. (2015).,
Handheld photoacoustic probe to detect both melanoma depth and volume at high speed in vivo., Journal of Biophotonics, 8(11-12), 961-967. doi:10.1002/jbio.201400143 [doi]
Chomet M, Schreurs M, Bolijn MJ, Verlaan M, Beaino W, Brown K, Poot AJ, Windhorst AD, Gill H, Marik J, Williams S, Cowell J, Gasser G, Mindt TL, van Dongen GAMS, Vugts DJ.,
Head-to-head comparison of DFO* and DFO chelators: selection of the best candidate for clinical (89)Zr-immuno-PET, Eur J Nucl Med Mol Imaging. 2021 Mar;48(3):694-707. doi: 10.1007/s00259-020-05002-7. Epub 2020 Sep 5.
Arzumanyan, A., Sambandam, V., Clayton, M. M., Choi, S. S., Xie, G., Diehl, A. M., . . . Feitelson, M. A. (2012).,
Hedgehog signaling blockade delays hepatocarcinogenesis induced by hepatitis B virus X protein., Cancer Research, 72(22), 5912-5920. doi:10.1158/0008-5472.CAN-12-2329 [doi]
Elwaie TA, Abbas SE, Aly EI, George RF, Ali H, Kraiouchkine N, Abdelwahed KS, Fandy TE, El Sayed KA, Abd Elmageed ZY, Ali HI.,
HER2 Kinase-Targeted Breast Cancer Therapy: Design, Synthesis, and In Vitro and In Vivo Evaluation of Novel Lapatinib Congeners as Selective and Potent HER2 Inhibitors with Favorable Metabolic Stability, J Med Chem. 2020 Dec 24;63(24):15906-15945. doi: 10.1021/acs.jmedchem.0c01647. Epub 2020 Dec 14.
Phillips DC, Buchanan FG, Cheng D, Solomon LR, Xiao Y, Xue J, Tahir SK, Smith ML, Zhang H, Widomski D, Abraham VC, Xu N, Liu Z, Zhou L, DiGiammarino E, Lu X, Rudra-Ganguly N, Trela B, Morgan-Lappe SE.,
Hexavalent TRAIL Fusion Protein Eftozanermin Alfa Optimally Clusters Apoptosis-Inducing TRAIL Receptors to Induce On-Target Antitumor Activity in Solid Tumors, Cancer Res. 2021 Jun 15;81(12):3402-3414. doi: 10.1158/0008-5472.CAN-20-2178. Epub 2021 Mar 9.
Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V.,
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer, Clin Cancer Res. 2021 Sep 30. doi: 10.1158/1078-0432.CCR-21-1810. Online ahead of print.
Sánchez-Guixé M, Hierro C, Jiménez J, Viaplana C, Villacampa G, Monelli E, Brasó-Maristany F, Ogbah Z, Parés M, Guzmán M, Grueso J, Rodríguez O, Oliveira M, Azaro A, Garralda E, Tabernero J, Casanovas O, Scaltriti M, Prat A, Dienstmann R, Nuciforo P, Saura C, Graupera M, Vivancos A, Rodon J, Serra V.,
High FGFR1-4 mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer, Clin Cancer Res. 2022 Jan 1;28(1):137-149. doi: 10.1158/1078-0432.CCR-21-1810. Epub 2021 Sep 30.
Huhtaniemi R, Sipilä P, Junnila A, Oksala R, Knuuttila M, Mehmood A, Aho E, Laajala TD, Aittokallio T, Laiho A, Elo L, Ohlsson C, Thulin MH, Kallio P, Mäkelä S, Mustonen MVJ, Poutanen M.,
High intratumoral dihydrotestosterone is associated with antiandrogen resistance in VCaP prostate cancer xenografts in castrated mice, iScience. 2022 Apr 25;25(5):104287. doi: 10.1016/j.isci.2022.104287. eCollection 2022 May 20.
Kumar N, Rachagani S, Natarajan G, Crook A, Gopal T, Rajamanickam V, Kaushal JB, Nagabhishek SN, Powers R, Batra SK, Saraswathi V.,
Histidine Enhances the Anticancer Effect of Gemcitabine against Pancreatic Cancer via Disruption of Amino Acid Homeostasis and Oxidant-Antioxidant Balance., Cancers (Basel). 2023 May 3;15(9). pii: 2593. doi: 10.3390/cancers15092593.
Efimova, E. V., Ricco, N., Labay, E., Mauceri, H. J., Flor, A. C., Ramamurthy, A., . . . Kron, S. J. (2018).,
HMG-CoA reductase inhibition delays DNA repair and promotes senescence after tumor irradiation., Molecular Cancer Therapeutics, 17(2), 407-418. doi:10.1158/1535-7163.MCT-17-0288 [doi]
Lelj-Garolla, B., Kumano, M., Beraldi, E., Nappi, L., Rocchi, P., Ionescu, D. N., . . . Gleave, M. E. (2015).,
Hsp27 inhibition with OGX-427 sensitizes non-small cell lung cancer cells to erlotinib and chemotherapy., Molecular Cancer Therapeutics, 14(5), 1107-1116. doi:10.1158/1535-7163.MCT-14-0866 [doi]
Lu, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018).,
Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1., Molecular Cancer Research : MCR, 16(10), 1458-1469. doi:10.1158/1541-7786.MCR-17-0637 [doi]
Lu, Y., Liu, Y., Oeck, S., & Glazer, P. M. (2018).,
Hypoxia promotes resistance to EGFR inhibition in NSCLC cells via the histone demethylases, LSD1 and PLU-1., Molecular Cancer Research : MCR, 16(10), 1458-1469. doi:10.1158/1541-7786.MCR-17-0637 [doi]
Serra V, Wang AT, Castroviejo-Bermejo M, Polanska UM, Palafox M, Herencia-Ropero A, Jones GN, Lai Z, Armenia J, Michopoulos F, Llop-Guevara A, Brough R, Gulati A, Pettitt SJ, Bulusu KC, Nikkilä J, Wilson Z, Hughes A, Wijnhoven PWG, Ahmed A, Bruna A, Gris-Oliver A, Guzman M, Rodríguez O, Grueso J, Arribas J, Cortés J, Saura C, Lau A, Critchlow S, Dougherty B, Caldas C, Mills GB, Barrett JC, Forment JV, Cadogan E, Lord CJ, Cruz C, Balmaña J, O'Connor MJ.,
Identification of a Molecularly-Defined Subset of Breast and Ovarian Cancer Models that Respond to WEE1 or ATR Inhibition, Overcoming PARP Inhibitor Resistance, Clin Cancer Res. 2022 Oct 14;28(20):4536-4550. doi: 10.1158/1078-0432.CCR-22-0568.
Fell JB, Fischer JP, Baer BR, Blake JF, Bouhana K, Briere DM, Brown KD, Burgess LE, Burns AC, Burkard MR, Chiang H, Chicarelli MJ, Cook AW, Gaudino JJ, Hallin J, Hanson L, Hartley DP, Hicken EJ, Hingorani GP, Hinklin RJ, Mejia MJ, Olson P, Otten JN, Rhodes SP, Rodriguez ME, Savechenkov P, Smith DJ, Sudhakar N, Sullivan FX, Tang TP, Vigers GP, Wollenberg L, Christensen JG, Marx MA.,
Identification of the Clinical Development Candidate MRTX849, a Covalent KRAS(G12C) Inhibitor for the Treatment of Cancer, J Med Chem. 2020 Jul 9;63(13):6679-6693. doi: 10.1021/acs.jmedchem.9b02052. Epub 2020 Apr 6.
Abourbeh, G., Itamar, B., Salnikov, O., Beltsov, S., & Mishani, E. (2015).,
Identifying erlotinib-sensitive non-small cell lung carcinoma tumors in mice using [(11)C]erlotinib PET., EJNMMI Research, 5, 4-014-0080-0. eCollection 2015. doi:10.1186/s13550-014-0080-0 [doi]
Gargini R, Segura-Collar B, Garranzo-Asensio M, Hortigüela R, Iglesias-Hernández P, Lobato-Alonso D, Moreno-Raja M, Esteban-Martin S, Sepúlveda-Sánchez JM, Nevola L, Sánchez-Gómez P.,
IDP-410: a Novel Therapeutic Peptide that Alters N-MYC Stability and Reduces Angiogenesis and Tumor Progression in Glioblastomas, Neurotherapeutics. 2022 Jan;19(1):408-420. doi: 10.1007/s13311-021-01176-6. Epub 2022 Jan 31.
Attaluri, A., Seshadri, M., Mirpour, S., Wabler, M., Marinho, T., Furqan, M., . . . Liapi, E. (2016),
Image-guided thermal therapy with a dual-contrast magnetic nanoparticle formulation: A feasibility study. International Journal of Hyperthermia, The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group, 32(5), 543-557. doi:10.3109/02656736.2016.1159737 [doi]
Brignole, C., Pastorino, F., Marimpietri, D., Pagnan, G., Pistorio, A., Allen, T. M., . . . Ponzoni, M. (2004).,
Immune cell-mediated antitumor activities of GD2-targeted liposomal c-myb antisense oligonucleotides containing CpG motifs., Journal of the National Cancer Institute, 96(15), 1171-1180. doi:10.1093/jnci/djh221 [doi]
Alvero AB, Fox A, Madina BR, Krady MM, Gogoi R, Chehade H, Nakaar V, Almassian B, Yarovinsky TO, Rutherford T, Mor G.,
Immune modulation of innate and adaptive responses restores immune surveillance and establishes anti-tumor immunological memory., Cancer Immunol Res. 2023 Dec 11. doi: 10.1158/2326-6066.CIR-23-0127. [Epub ahead of print]
Sun, H., England, C. G., Hernandez, R., Graves, S. A., Majewski, R. L., Kamkaew, A., . . . Cai, W. (2016).,
ImmunoPET for assessing the differential uptake of a CD146-specific monoclonal antibody in lung cancer, European Journal of Nuclear Medicine and Molecular Imaging, 43(12), 2169-2179. doi:10.1007/s00259-016-3442-1 [doi]
Hernandez, R., England, C. G., Yang, Y., Valdovinos, H. F., Liu, B., Wong, H. C., . . . Cai, W. (2017).,
ImmunoPET imaging of tissue factor expression in pancreatic cancer with (89)zr-df-ALT-836, Journal of Controlled Release : Official Journal of the Controlled Release Society, 264, 160-168. doi:S0168-3659(17)30796-4 [pii]
Li M, Wei W, Barnhart TE, Jiang D, Cao T, Fan K, Engle JW, Liu J, Chen W, Cai W.,
ImmunoPET/NIRF/Cerenkov multimodality imaging of ICAM-1 in pancreatic ductal adenocarcinoma, Eur J Nucl Med Mol Imaging. 2021 Aug;48(9):2737-2748. doi: 10.1007/s00259-021-05216-3. Epub 2021 Feb 3.
Guffanti F, Alvisi MF, Caiola E, Ricci F, De Maglie M, Soldati S, Ganzinelli M, Decio A, Giavazzi R, Rulli E, Damia G.,
Impact of ERCC1, XPF and DNA Polymerase ? Expression on Platinum Response in Patient-Derived Ovarian Cancer Xenografts, Cancers (Basel). 2020 Aug 24;12(9):2398. doi: 10.3390/cancers12092398.
Heinrich, A. K., Lucas, H., Schindler, L., Chytil, P., Etrych, T., Mader, K., & Mueller, T. (2016),
Improved tumor-specific drug accumulation by polymer therapeutics with pH-sensitive drug release overcomes chemotherapy resistance, Molecular Cancer Therapeutics, 15(5), 998-1007. doi:10.1158/1535-7163.MCT-15-0824 [doi]
Hughes, P. E., Rex, K., Caenepeel, S., Yang, Y., Zhang, Y., Broome, M. A., . . . Coxon, A. (2016).,
In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models., Molecular Cancer Therapeutics, 15(7), 1568-1579. doi:10.1158/1535-7163.MCT-15-0871 [doi]
Baldini E, Presutti D, Favoriti P, Santini S, Papoff G, Tuccilli C, Carletti R, Di Gioia C, Lori E, Ferent IC, Gagliardi F, Catania A, Pironi D, Tripodi D, D'Andrea V, Sorrenti S, Ruberti G, Ulisse S.,
In Vitro and In Vivo Effects of the Urokinase Plasminogen Activator Inhibitor WX-340 on Anaplastic Thyroid Cancer Cell Lines, Int J Mol Sci. 2022 Mar 28;23(7):3724. doi: 10.3390/ijms23073724.
Xia, C. F., Chen, G., Gangadharmath, U., Gomez, L. F., Liang, Q., Mu, F., . . . Kolb, H. C. (2013),
In vitro and in vivo evaluation of the caspase-3 substrate-based radiotracer [(18)F]-CP18 for PET imaging of apoptosis in tumors., Molecular Imaging and Biology : MIB : The Official Publication of the Academy of Molecular Imaging, 15(6), 748-757. doi:10.1007/s11307-013-0646-7 [doi]
He, Y., Wang, L., Shi, J., Yao, J., Li, L., Zhang, R., . . . Wang, L. V. (2016),
In vivo label-free photoacoustic flow cytography and on-the-spot laser killing of single circulating melanoma cells, Scientific Reports, 6, 39616. doi:10.1038/srep39616 [doi]
Irrera P, Consolino L, Roberto M, Capozza M, Dhakan C, Carella A, Corrado A, Villano D, Anemone A, Navarro-Tableros V, Bracesco M, Dastrù W, Aime S, Longo DL.,
In Vivo MRI-CEST Tumor pH Imaging Detects Resistance to Proton Pump Inhibitors in Human Prostate Cancer Murine Models, Cancers (Basel). 2022 Oct 7;14(19):4916. doi: 10.3390/cancers14194916.
Rybczynska, A. A., de Bruyn, M., Ramakrishnan, N. K., de Jong, J. R., Elsinga, P. H., Helfrich, W., . . . van Waarde, A. (2013).,
In vivo responses of human A375M melanoma to a sigma ligand: 18F-FDG PET imaging., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 54(9), 1613-1620. doi:10.2967/jnumed.113.122655 [doi]
Colmegna, B., Uboldi, S., Frapolli, R., Licandro, S. A., Panini, N., Galmarini, C. M., . . . D'Incalci, M. (2015),
Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin., British Journal of Cancer, 113(12), 1687-1693. doi:10.1038/bjc.2015.407 [doi]
Gunsalus, K. T., Wagoner, M. P., Meyer, K., Potter, W. B., Schoenike, B., Kim, S., . . . Roopra, A. (2012).,
Induction of the RNA regulator LIN28A is required for the growth and pathogenesis of RESTless breast tumors, Cancer Research, 72(13), 3207-3216. doi:10.1158/0008-5472.CAN-11-1639 [doi]
Wang, X., Solban, N., Khanna, P., Callea, M., Song, J., Alsop, D. C., . . . Bhatt, R. S. (2016).,
Inhibition of ALK1 signaling with dalantercept combined with VEGFR TKI leads to tumor stasis in renal cell carcinoma., Oncotarget, 7(27), 41857-41869. doi:10.18632/oncotarget.9621 [doi]
Zhou Q, Howard ME, Tu X, Zhu Q, Denbeigh JM, Remmes NB, Herman MG, Beltran CJ, Yuan J, Greipp PT, Boughey JC, Wang L, Johnson N, Goetz MP, Sarkaria JN, Lou Z, Mutter RW.,
Inhibition of ATM Induces Hypersensitivity to Proton Irradiation by Upregulating Toxic End Joining, Cancer Res. 2021 Jun 15;81(12):3333-3346. doi: 10.1158/0008-5472.CAN-20-2960. Epub 2021 Feb 17.
Cook Sangar, M. L., Genovesi, L. A., Nakamoto, M. W., Davis, M. J., Knobluagh, S. E., Ji, P., . . . Olson, J. M. (2017).,
Inhibition of CDK4/6 by palbociclib significantly extends survival in medulloblastoma patient-derived xenograft mouse models., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(19), 5802-5813. doi:10.1158/1078-0432.CCR-16-2943 [doi]
Zhang, Y., Wang, Q., Chen, L., & Yang, H. S. (2015),
Inhibition of p70S6K1 activation by Pdcd4 overcomes the resistance to an IGF-1R/IR inhibitor in colon carcinoma cells., Molecular Cancer Therapeutics, 14(3), 799-809. doi:10.1158/1535-7163.MCT-14-0648 [doi]
Shao, C., Ahmad, N., Hodges, K., Kuang, S., Ratliff, T., & Liu, X. (2015).,
Inhibition of polo-like kinase 1 (Plk1) enhances the antineoplastic activity of metformin in prostate cancer., The Journal of Biological Chemistry, 290(4), 2024-2033. doi:10.1074/jbc.M114.596817 [doi]
Gómez-Aleza C, Nguyen B, Yoldi G, Ciscar M, Barranco A, Hernández-Jiménez E, Maetens M, Salgado R, Zafeiroglou M, Pellegrini P, Venet D, Garaud S, Trinidad EM, Benítez S, Vuylsteke P, Polastro L, Wildiers H, Simon P, Lindeman G, Larsimont D, Van den Eynden G, Velghe C, Rothé F, Willard-Gallo K, Michiels S, Muñoz P, Walzer T, Planelles L, Penninger J, Azim HA Jr, Loi S, Piccart M, Sotiriou C, González-Suárez E.,
Inhibition of RANK signaling in breast cancer induces an anti-tumor immune response orchestrated by CD8+ T cells, Nat Commun. 2020 Dec 10;11(1):6335. doi: 10.1038/s41467-020-20138-8.
Humeau J, Sauvat A, Cerrato G, Xie W, Loos F, Iannantuoni F, Bezu L, Lévesque S, Paillet J, Pol J, Leduc M, Zitvogel L, de Thé H, Kepp O, Kroemer G.,
Inhibition of transcription by dactinomycin reveals a new characteristic of immunogenic cell stress, EMBO Mol Med. 2020 May 8;12(5):e11622. doi: 10.15252/emmm.201911622. Epub 2020 Apr 23.
Cao W, Shen R, Richard S, Liu Y, Jalalirad M, Cleary MP, D'Assoro AB, Gradilone SA, Yang DQ.,
Inhibition of triple‑negative breast cancer proliferation and motility by reactivating p53 and inhibiting overactivated Akt, Oncol Rep. 2022 Feb;47(2):41. doi: 10.3892/or.2021.8252. Epub 2021 Dec 27.
Zhou K, Cheong JE, Krishnaji ST, Ghalali A, Fu H, Sui L, Alix-Panabières C, Cayrefourcq L, Bielenberg D, Sun L, Zetter B.,
Inhibition of Wnt Signaling in Colon Cancer Cells via an Oral Drug that Facilitates TNIK Degradation, Mol Cancer Ther. 2023 Jan 3;22(1):25-36. doi: 10.1158/1535-7163.MCT-21-0801.
Puente, P., Fettig, N., Luderer, M. J., Jin, A., Shah, S., Muz, B., . . . Azab, A. K. (2018).,
Injectable hydrogels for localized chemotherapy and radiotherapy in brain tumors., Journal of Pharmaceutical Sciences, 107(3), 922-933. doi:S0022-3549(17)30829-8 [pii]
Wu, Jiao; Minikes, Alexander M; Gao, Minghui; Bian, Huijie; Li, Yong; Stockwell, Brent R; Chen, Zhi-Nan; Jiang, Xuejun;,
Intercellular interaction dictates cancer cell ferroptosis via NF2-YAP signalling, Nature Vol.572, 2019
Hwang SY, Park S, Jo H, Hee Seo S, Jeon KH, Kim S, Jung AR, Song C, Ahn M, Yeon Kwak S, Lee HJ, Uesugi M, Na Y, Kwon Y.,
Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers, J Adv Res. 2022 Aug 10:S2090-1232(22)00171-0. doi: 10.1016/j.jare.2022.08.003. Online ahead of print.
Hwang SY, Park S, Jo H, Hee Seo S, Jeon KH, Kim S, Jung AR, Song C, Ahn M, Yeon Kwak S, Lee HJ, Uesugi M, Na Y, Kwon Y.,
Interrupting specific hydrogen bonds between ELF3 and MED23 as an alternative drug resistance-free strategy for HER2-overexpressing cancers., J Adv Res. 2023 May;47:173-187. doi: 10.1016/j.jare.2022.08.003. Epub 2022 Aug 10.
Wang, W., Cho, H. Y., Rosenstein-Sisson, R., Marin Ramos, N. I., Price, R., Hurth, K., . . . Chen, T. C. (2018),
Intratumoral delivery of bortezomib: Impact on survival in an intracranial glioma tumor model, Journal of Neurosurgery, 128(3), 695-700. doi:10.3171/2016.11.JNS161212 [doi]
Relation, T., Yi, T., Guess, A. J., La Perle, K., Otsuru, S., Hasgur, S., . . . Horwitz, E. M. (2018).,
Intratumoral delivery of interferongamma-secreting mesenchymal stromal cells repolarizes tumor-associated macrophages and suppresses neuroblastoma proliferation in vivo., Stem Cells (Dayton, Ohio), 36(6), 915-924. doi:10.1002/stem.2801 [doi]
Eluu SC, Obayemi JD, Salifu AA, Yiporo D, Oko AO, Aina T, Oparah JC, Ezeala CC, Etinosa PO, Ugwu CM, Esimone CO, Soboyejo WO.,
In-vivo studies of targeted and localized cancer drug release from microporous poly-di-methyl-siloxane (PDMS) devices for the treatment of triple negative breast cancer., Sci Rep. 2024 Jan 2;14(1):31. doi: 10.1038/s41598-023-50656-6.
Turchan, W. T., Shapiro, R. H., Sevigny, G. V., Chin-Sinex, H., Pruden, B., & Mendonca, M. S. (2016).,
Irradiated human endothelial progenitor cells induce bystander killing in human non-small cell lung and pancreatic cancer cells, International Journal of Radiation Biology, 92(8), 427-433. doi:10.1080/09553002.2016.1186299 [doi]
Wu Q, Tian AL, Durand S, Aprahamian F, Nirmalathasan N, Xie W, Liu P, Zhao L, Zhang S, Pan H, Carmona-Gutierrez D, Madeo F, Tu Y, Kepp O, Kroemer G.,
Isobacachalcone induces autophagy and improves the outcome of immunogenic chemotherapy, Cell Death Dis. 2020 Nov 26;11(11):1015. doi: 10.1038/s41419-020-03226-x.
Bouguenina H, Nicolaou S, Le Bihan YV, Bowling EA, Calderon C, Caldwell JJ, Harrington B, Hayes A, McAndrew PC, Mitsopoulos C, Sialana FJ, Scarpino A, Stubbs M, Thapaliya A, Tyagi S, Wang HZ, Wood F, Burke R, Raynaud F, Choudhary J, van Montfort RLM, Sadok A, et al.,
iTAG an optimized IMiD-induced degron for targeted protein degradation in human and murine cells., iScience. 2023 Jun 7;26(7):107059. doi: 10.1016/j.isci.2023.107059. eCollection 2023 Jul 21.
Imig JD, Hye Khan MA, Burkhan A, Chen G, Adebesin AM, Falck JR.,
Kidney-Targeted Epoxyeicosatrienoic Acid Analog, EET-F01, Reduces Inflammation, Oxidative Stress, and Cisplatin-Induced Nephrotoxicity, Int J Mol Sci. 2021 Mar 10;22(6):2793. doi: 10.3390/ijms22062793.
Gelsomino L, Naimo GD, Malivindi R, Augimeri G, Panza S, Giordano C, Barone I, Bonofiglio D, Mauro L, Catalano S, Andò S.,
Knockdown of Leptin Receptor Affects Macrophage Phenotype in the Tumor Microenvironment Inhibiting Breast Cancer Growth and Progression, Cancers (Basel). 2020 Jul 27;12(8):2078. doi: 10.3390/cancers12082078.
Dwivedi SKD, Shameer K, Dey A, Mustafi SB, Xiong X, Bhattacharya U, Neizer-Ashun F, Rao G, Wang Y, Ivan C, Yang D, Dudley JT, Xu C, Wren JD, Mukherjee P, Bhattacharya R.,
KRCC1: A potential therapeutic target in ovarian cancer, FASEB J. 2020 Feb;34(2):2287-2300. doi: 10.1096/fj.201902259R. Epub 2019 Dec 23.
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM.,
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma, Biochem Pharmacol. 2023 Jan 2;208:115408. doi: 10.1016/j.bcp.2022.115408. Online ahead of print.
Pascual-Pasto G, Resa-Pares C, Castillo-Ecija H, Aschero R, Baulenas-Farres M, Vila-Ubach M, Burgueño V, Balaguer-Lluna L, Cuadrado-Vilanova M, Olaciregui NG, Martinez-Velasco N, Perez-Jaume S, de Alava E, Tirado OM, Lavarino C, Mora J, Carcaboso AM.,
Low Bcl-2 is a robust biomarker of sensitivity to nab-paclitaxel in Ewing sarcoma., Biochem Pharmacol. 2023 Feb;208:115408. doi: 10.1016/j.bcp.2022.115408. Epub 2023 Jan 2.
Haedicke, K., Graefe, S., Teichgraeber, U., & Hilger, I. (2016).,
Lowering photosensitizer doses and increasing fluences induce apoptosis in tumor bearing mice, Biomedical Optics Express, 7(7), 2641-2649. doi:10.1364/BOE.7.002641 [doi]
Santamaria Nunez, G., Robles, C. M., Giraudon, C., Martinez-Leal, J. F., Compe, E., Coin, F., . . . Egly, J. M. (2016).,
Lurbinectedin specifically triggers the degradation of phosphorylated RNA polymerase II and the formation of DNA breaks in cancer cells., Molecular Cancer Therapeutics, 15(10), 2399-2412. doi:1535-7163.MCT-16-0172 [pii]
Johnson, J. L., Dia, V. P., Wallig, M., & Gonzalez de Mejia, E. (2015),
Luteolin and gemcitabine protect against pancreatic cancer in an orthotopic mouse model., Pancreas, 44(1), 144-151. doi:10.1097/MPA.0000000000000215 [doi]
Roger E, Gout J, Arnold F, Beutel AK, Müller M, Abaei A, Barth TFE, Rasche V, Seufferlein T, Perkhofer L, Kleger A.,
Maintenance Therapy for ATM-Deficient Pancreatic Cancer by Multiple DNA Damage Response Interferences after Platinum-Based Chemotherapy, Cells. 2020 Sep 16;9(9):2110. doi: 10.3390/cells9092110.
Lodestijn SC, Miedema DM, Lenos KJ, Nijman LE, Belt SC, El Makrini K, Lecca MC, Waasdorp C, van den Bosch T, Bijlsma MF, Vermeulen L.,
Marker-free lineage tracing reveals an environment-instructed clonogenic hierarchy in pancreatic cancer, Cell Rep. 2021 Oct 19;37(3):109852. doi: 10.1016/j.celrep.2021.109852.
Bernardo, M. M., Kaplun, A., Dzinic, S. H., Li, X., Irish, J., Mujagic, A., . . . Sheng, S. (2015),
Maspin expression in prostate tumor cells averts stemness and stratifies drug sensitivity, Cancer Research, 75(18), 3970-3979. doi:10.1158/0008-5472.CAN-15-0234 [doi]
Kalev P, Hyer ML, Gross S, Konteatis Z, Chen CC, Fletcher M, Lein M, Aguado-Fraile E, Frank V, Barnett A, Mandley E, Goldford J, Chen Y, Sellers K, Hayes S, Lizotte K, Quang P, Tuncay Y, Clasquin M, Peters R, Weier J, Simone E, Murtie J, Liu W, Nagaraja R, Dang L, Sui Z, Biller SA, Travins J, Marks KM, Marjon K.,
MAT2A Inhibition Blocks the Growth of MTAP-Deleted Cancer Cells by Reducing PRMT5-Dependent mRNA Splicing and Inducing DNA Damage, Cancer Cell. 2021 Feb 8;39(2):209-224.e11. doi: 10.1016/j.ccell.2020.12.010. Epub 2021 Jan 14.
Crotty EE, Smith SMC, Brasel K, Pakiam F, Girard EJ, Connor YD, Zindy F, Mhyre AJ, Roussel MF, Olson JM.,
Medulloblastoma recurrence and metastatic spread are independent of colony-stimulating factor 1 receptor signaling and macrophage survival, J Neurooncol. 2021 Jun;153(2):225-237. doi: 10.1007/s11060-021-03767-x. Epub 2021 May 8.
Franklin DA, Sharick JT, Ericsson-Gonzalez PI, Sanchez V, Dean PT, Opalenik SR, Cairo S, Judde JG, Lewis MT, Chang JC, Sanders ME, Cook RS, Skala MC, Bordeaux J, Orozco Bender J, Vaupel C, Geiss G, Hinerfeld D, Balko JM.,
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC, JCI Insight. 2020 Aug 6;5(15):e134290. doi: 10.1172/jci.insight.134290.
García-García , Celina; Rivas, Martín A; Ibrahim, Yasir H; Calvo, María Teresa; Gris-Oliver, Albert; Rodríguez , Olga; Grueso, Judit; Antón, Pilar; Guzmán, Marta; Aura, Claudia; Nuciforo, Paolo; Jessen, Katti; Argilés, Guillem; Dienstmann, Rodrigo; Bertotti, Andrea; Trusolino, Livio; Matito, Judit; Vivancos, Ana; Chicote, Irene; Palmer, Héctor G; Tabernero, Josep; Scaltriti, Maurizio; Baselga, José; Serra, Violeta,
MEK plus PI3K/mTORC1/2 Therapeutic Efficacy Is Impacted by TP53 Mutation in Preclinical Models of Colorectal Cancer., Clinical cancer research : an official journal of the American Association for Cancer Research Vol.21, 2015
Sharick JT, Walsh CM, Sprackling CM, Pasch CA, Pham DL, Esbona K, Choudhary A, Garcia-Valera R, Burkard ME, McGregor SM, Matkowskyj KA, Parikh AA, Meszoely IM, Kelley MC, Tsai S, Deming DA, Skala MC.,
Metabolic Heterogeneity in Patient Tumor-Derived Organoids by Primary Site and Drug Treatment, Front Oncol. 2020 May 15;10:553. doi: 10.3389/fonc.2020.00553. eCollection 2020.
Yan, S. B., Um, S. L., Peek, V. L., Stephens, J. R., Zeng, W., Konicek, B. W., . . . Walgren, R. A. (2018).,
MET-targeting antibody (emibetuzumab) and kinase inhibitor (merestinib) as single agent or in combination in a cancer model bearing MET exon 14 skipping., Investigational New Drugs, 36(4), 536-544. doi:10.1007/s10637-017-0545-x [doi]
Punturi NB, Seker S, Devarakonda V, Mazumder A, Kalra R, Chen CH, Li S, Primeau T, Ellis MJ, Kavuri SM, Haricharan S.,
Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer, Nat Commun. 2021 May 19;12(1):2940. doi: 10.1038/s41467-021-23271-0.
Gonzalvez F, Vincent S, Baker TE, Gould AE, Li S, Wardwell SD, Nadworny S, Ning Y, Zhang S, Huang WS, Hu Y, Li F, Greenfield MT, Zech SG, Das B, Narasimhan NI, Clackson T, Dalgarno D, Shakespeare WC, Fitzgerald M, Chouitar J, Griffin RJ, Liu S, Wong KK, Zhu X, Rivera VM.,
Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non-Small Cell Lung Cancer, Cancer Discov. 2021 Jul;11(7):1672-1687. doi: 10.1158/2159-8290.CD-20-1683. Epub 2021 Feb 25.
Lv X, Lu X, Cao J, Luo Q, Ding Y, Peng F, Pataer A, Lu D, Han D, Malmberg E, Chan DW, Wang X, Savage SR, Mao S, Yu J, Peng F, Yan L, Meng H, Maneix L, Han Y, Chen Y, Yao W, et al.,
Modulation of the proteostasis network promotes tumor resistance to oncogenic KRAS inhibitors., Science. 2023 Sep 8;381(6662):eabn4180. doi: 10.1126/science.abn4180. Epub 2023 Sep 8.
Yan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G.,
Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone, Cell Rep. 2020 Jun 30;31(13):107840. doi: 10.1016/j.celrep.2020.107840.
Yan P, Patel HJ, Sharma S, Corben A, Wang T, Panchal P, Yang C, Sun W, Araujo TL, Rodina A, Joshi S, Robzyk K, Gandu S, White JR, de Stanchina E, Modi S, Janjigian YY, Hill EG, Liu B, Erdjument-Bromage H, Neubert TA, Que NLS, Li Z, Gewirth DT, Taldone T, Chiosis G.,
Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone, Cell Rep. 2020 Jun 30;31(13):107840. doi: 10.1016/j.celrep.2020.107840.
Morcillo, M. A., Garcia de Lucas, A., Oteo, M., Romero, E., Magro, N., Ibanez, M., . . . Martinez-Torrecuadrada, J. (2018).,
MT1-MMP as a PET imaging biomarker for pancreas cancer management., Contrast Media & Molecular Imaging, 2018, 8382148. doi:10.1155/2018/8382148 [doi]
Kumar, A., Dhar, S., Campanelli, G., Butt, N. A., Schallheim, J. M., Gomez, C. R., & Levenson, A. S. (2018),
MTA1 drives malignant progression and bone metastasis in prostate cancer., Molecular Oncology, 12(9), 1596-1607. doi:10.1002/1878-0261.12360 [doi]
Haedicke, K., Kozlova, D., Grafe, S., Teichgraber, U., Epple, M., & Hilger, I. (2015).,
Multifunctional calcium phosphate nanoparticles for combining near-infrared fluorescence imaging and photodynamic therapy, Acta Biomaterialia, 14, 197-207. doi:10.1016/j.actbio.2014.12.009 [doi]
Zhu Y, Yue P, Dickinson CF, Yang JK, Datanagan K, Zhai N, Zhang Y, Miklossy G, Lopez-Tapia F, Tius MA, Turkson J.,
Natural product preferentially targets redox and metabolic adaptations and aberrantly active STAT3 to inhibit breast tumor growth in vivo, Cell Death Dis. 2022 Dec 6;13(12):1022. doi: 10.1038/s41419-022-05477-2.
Veeraraghavan J, Gutierrez C, Sethunath V, Mehravaran S, Giuliano M, Shea MJ, Mitchell T, Wang T, Nanda S, Pereira R, Davis R, Goutsouliak K, Qin L, De Angelis C, Diala I, Lalani AS, Nagi C, Hilsenbeck SG, Rimawi MF, Osborne CK, Schiff R.,
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models, NPJ Breast Cancer. 2021 May 27;7(1):63. doi: 10.1038/s41523-021-00274-0.
Wang, P. Y., Swain, H. M., Kunkler, A. L., Chen, C. Y., Hutzen, B. J., Arnold, M. A., . . . Cripe, T. P. (2016).,
Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility., Gene Therapy, 23(2), 135-143. doi:10.1038/gt.2015.105 [doi]
Zheng ZY, Anurag M, Lei JT, Cao J, Singh P, Peng J, Kennedy H, Nguyen NC, Chen Y, Lavere P, Li J, Du XH, Cakar B, Song W, Kim BJ, Shi J, Seker S, Chan DW, Zhao GQ, Chen X, Banks KC, Lanman RB, Shafaee MN, Zhang XH, Vasaikar S, Zhang B, Hilsenbeck SG, Li W, Foulds CE, Ellis MJ, Chang EC.,
Neurofibromin Is an Estrogen Receptor-α Transcriptional Co-repressor in Breast Cancer, Cancer Cell. 2020 Mar 16;37(3):387-402.e7. doi: 10.1016/j.ccell.2020.02.003. Epub 2020 Mar 5.
Li X, Chen Y, Bai L, Zhao R, Wu Y, Xie ZR, Wu JM, Bowen NJ, Danaher A, Cook N, Li D, Qui M, Du Y, Fu H, Osunkoya AO, Kucuk O, Wu D.,
Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models., Br J Cancer. 2023 Sep;129(5):884-894. doi: 10.1038/s41416-023-02359-y. Epub 2023 Jul 20.
Yu, X., Liu, F., Zeng, L., He, F., Zhang, R., Yan, S., . . . Chen, L. (2018).,
Niclosamide exhibits potent anticancer activity and synergizes with sorafenib in human renal cell cancer cells., Cellular Physiology and Biochemistry : International Journal of Experimental Cellular Physiology, Biochemistry, and Pharmacology, 47(3), 957-971. doi:10.1159/000490140 [doi]
Bousquet Mur E, Bernardo S, Papon L, Mancini M, Fabbrizio E, Goussard M, Ferrer I, Giry A, Quantin X, Pujol JL, Calvayrac O, Moll HP, Glasson Y, Pirot N, Turtoi A, CaĂąamero M, Wong KK, Yarden Y, Casanova E, Soria JC, Colinge J, Siebel CW, Mazieres J, Favre G, Paz-Ares L, Maraver A.,
Notch inhibition overcomes resistance to tyrosine kinase inhibitors in EGFR-driven lung adenocarcinoma, J Clin Invest. 2020 Feb 3;130(2):612-624. doi: 10.1172/JCI126896.
Chen, H., Jacobson, O., Niu, G., Weiss, I. D., Kiesewetter, D. O., Liu, Y., . . . Chen, X. (2017).,
Novel "add-on" molecule based on evans blue confers superior pharmacokinetics and transforms drugs to theranostic agents. Journal of Nuclear Medicin, Official Publication, Society of Nuclear Medicine, 58(4), 590-597. doi:10.2967/jnumed.116.182097 [doi]
Choi, A. H., O'Leary, M. P., Chaurasiya, S., Lu, J., Kim, S. I., Fong, Y., & Chen, N. G. (2018).,
Novel chimeric parapoxvirus CF189 as an oncolytic immunotherapy in triple-negative breast cancer, Surgery, 163(2), 336-342. doi:S0039-6060(17)30670-0 [pii]
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE.,
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response, Cancer Lett. 2023 Jan 16:216062. doi: 10.1016/j.canlet.2023.216062. Online ahead of print.
Kleczko EK, Le AT, Hinz TK, Nguyen TT, Navarro A, Hu CJ, Selman AM, Clambey ET, Merrick DT, Lu S, Weiser-Evans M, Nemenoff RA, Heasley LE.,
Novel EGFR-mutant mouse models of lung adenocarcinoma reveal adaptive immunity requirement for durable osimertinib response., Cancer Lett. 2023 Mar 1;556:216062. doi: 10.1016/j.canlet.2023.216062. Epub 2023 Jan 16.
Kanthala, S., Banappagari, S., Gokhale, A., Liu, Y. Y., Xin, G., Zhao, Y., & Jois, S. (2015).,
Novel peptidomimetics for inhibition of HER2:HER3 heterodimerization in HER2-positive breast cancer., Chemical Biology & Drug Design, 85(6), 702-714. doi:10.1111/cbdd.12453 [doi]
Chen Y, Li X, Mamouni K, Yang Y, Danaher A, White J, Liu H, Kucuk O, Gera L, Wu D.,
Novel small-molecule LG1836 inhibits the in vivo growth of castration-resistant prostate cancer, Prostate. 2020 Sep;80(12):993-1005. doi: 10.1002/pros.24032. Epub 2020 Jun 19.
Gdowski A, Hayatshahi H, Fudala R, Joshi R, Liu J, Vishwanatha JK, Jeyarajah R, Guzik P, Ranjan AP.,
Novel Use of Hypoxia-Inducible Polymerizable Protein to Augment Chemotherapy for Pancreatic Cancer, Pharmaceutics. 2022 Jan 5;14(1):128. doi: 10.3390/pharmaceutics14010128.
Hegde, Ganapati V; de la Cruz, Cecile; Giltnane, Jennifer M; Crocker, Lisa; Venkatanarayan, Avinashnarayan; Schaefer, Gabriele; Dunlap, Debra; Hoeck, Joerg D; Piskol, Robert; Gnad, Florian; Modrusan, Zora; de Sauvage, Frederic J; Siebel, Christian W; Jackson, Erica L;,
NRG1 is a critical regulator of differentiation in TP63-driven squamous cell carcinoma, eLife Vol.8, 2019
Somwar R, Hofmann NE, Smith B, Odintsov I, Vojnic M, Linkov I, Tam A, Khodos I, Mattar MS, de Stanchina E, Flynn D, Ladanyi M, Drilon A, Shinde U, Davare MA.,
NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors, Commun Biol. 2020 Dec 16;3(1):776. doi: 10.1038/s42003-020-01508-w.
Servetto A, Kollipara R, Formisano L, Lin CC, Lee KM, Sudhan DR, Gonzalez-Ericsson PI, Chatterjee S, Guerrero-Zotano A, Mendiratta S, Akamatsu H, James N, Bianco R, Hanker AB, Kittler R, Arteaga CL.,
Nuclear FGFR1 Regulates Gene Transcription and Promotes Antiestrogen Resistance in ER(+) Breast Cancer, Clin Cancer Res. 2021 Aug 1;27(15):4379-4396. doi: 10.1158/1078-0432.CCR-20-3905. Epub 2021 May 19.
Vasciaveo A, Arriaga JM, de Almeida FN, Zou M, Douglass EF, Picech F, Shibata M, Rodriguez-Calero A, de Brot S, Mitrofanova A, Chua CW, Karan C, Realubit R, Pampou S, Kim JY, Afari SN, Mukhammadov T, Zanella L, Corey E, Alvarez MJ, Rubin MA, Shen MM, et al.,
OncoLoop: A Network-Based Precision Cancer Medicine Framework., Cancer Discov. 2023 Feb 6;13(2):386-409. doi: 10.1158/2159-8290.CD-22-0342.
Kottke T, Tonne J, Evgin L, Driscoll CB, van Vloten J, Jennings VA, Huff AL, Zell B, Thompson JM, Wongthida P, Pulido J, Schuelke MR, Samson A, Selby P, Ilett E, McNiven M, Roberts LR, Borad MJ, Pandha H, Harrington K, Melcher A, Vile RG.,
Oncolytic virotherapy induced CSDE1 neo-antigenesis restricts VSV replication but can be targeted by immunotherapy, Nat Commun. 2021 Mar 26;12(1):1930. doi: 10.1038/s41467-021-22115-1.
Lagerweij, T., Dusoswa, S. A., Negrean, A., Hendrikx, E. M. L., de Vries, H. E., Kole, J., . . . Wurdinger, T. (2017).,
Optical clearing and fluorescence deep-tissue imaging for 3D quantitative analysis of the brain tumor microenvironment., Angiogenesis, 20(4), 533-546. doi:10.1007/s10456-017-9565-6 [doi]
Pearson, H. E., Iida, M., Orbuch, R. A., McDaniel, N. K., Nickel, K. P., Kimple, R. J., . . . Wheeler, D. L. (2018).,
Overcoming resistance to cetuximab with honokiol, A small-molecule polyphenol., Molecular Cancer Therapeutics, 17(1), 204-214. doi:10.1158/1535-7163.MCT-17-0384 [doi]
Lubik, A. A., Nouri, M., Truong, S., Ghaffari, M., Adomat, H. H., Corey, E., . . . Buttyan, R. (2017),
Paracrine sonic hedgehog signaling contributes significantly to acquired steroidogenesis in the prostate tumor microenvironment., International Journal of Cancer, 140(2), 358-369. doi:10.1002/ijc.30450 [doi]
Staniszewska AD, Armenia J, King M, Michaloglou C, Reddy A, Singh M, San Martin M, Prickett L, Wilson Z, Proia T, Russell D, Thomas M, Delpuech O, O'Connor MJ, Leo E, Angell H, Valge-Archer V.,
PARP inhibition is a modulator of anti-tumor immune response in BRCA-deficient tumors, Oncoimmunology. 2022 Jun 18;11(1):2083755. doi: 10.1080/2162402X.2022.2083755. eCollection 2022.
Gozgit JM, Vasbinder MM, Abo RP, Kunii K, Kuplast-Barr KG, Gui B, Lu AZ, Molina JR, Minissale E, Swinger KK, Wigle TJ, Blackwell DJ, Majer CR, Ren Y, Niepel M, Varsamis ZA, Nayak SP, Bamberg E, Mo JR, Church WD, Mady ASA, Song J, Utley L, Rao PE, Mitchison TJ, Kuntz KW, Richon VM, Keilhack H.,
PARP7 negatively regulates the type I interferon response in cancer cells and its inhibition triggers antitumor immunity, Cancer Cell. 2021 Sep 13;39(9):1214-1226.e10. doi: 10.1016/j.ccell.2021.06.018. Epub 2021 Jul 22.
Yang A, Zhang Z, Chaurasiya S, Park AK, Lu J, Kim SI, Valencia H, Fong Y, Woo Y.,
Peritoneal-directed chimeric oncolytic virus CF17 prevents malignant ascites and improves survival in gastric cancer peritoneal metastases., Mol Ther Oncolytics. 2023 Oct 19;31:100734. doi: 10.1016/j.omto.2023.100734. eCollection 2023 Dec 19.
Stokes ME, Calvo V, Fujisawa S, Dudgeon C, Huang S, Ballal N, Shen L, Gasparek J, Betzenhauser M, Taylor SJ, Staschke KA, Rigby AC, Mulvihill MJ, Bose N, Lightcap ES, Surguladze D.,
PERK Inhibition by HC-5404 Sensitizes Renal Cell Carcinoma Tumor Models to Antiangiogenic Tyrosine Kinase Inhibitors., Clin Cancer Res. 2023 Dec 1;29(23):4870-4882. doi: 10.1158/1078-0432.CCR-23-1182.
Kamiyama, H., Rauenzahn, S., Shim, J. S., Karikari, C. A., Feldmann, G., Hua, L., . . . Eshleman, J. R. (2013).,
Personalized chemotherapy profiling using cancer cell lines from selectable mice., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 19(5), 1139-1146. doi:10.1158/1078-0432.CCR-12-2127 [doi]
Zhang Z, Yang A, Chaurasiya S, Park AK, Kim SI, Lu J, Olafsen T, Warner SG, Fong Y, Woo Y.,
PET imaging and treatment of pancreatic cancer peritoneal carcinomatosis after subcutaneous intratumoral administration of a novel oncolytic virus, CF33-hNIS-antiPDL1, Mol Ther Oncolytics. 2021 Dec 31;24:331-339. doi: 10.1016/j.omto.2021.12.022. eCollection 2022 Mar 17.
Steers GJ, O'Leary BR, Du J, Wagner BA, Carroll RS, Domann FE, Goswami PC, Buettner GR, Cullen JJ.,
Pharmacologic Ascorbate and DNMT Inhibitors Increase DUOX Expression and Peroxide-Mediated Toxicity in Pancreatic Cancer., Antioxidants (Basel). 2023 Aug 29;12(9). pii: 1683. doi: 10.3390/antiox12091683.
Alexander, M. S., Wilkes, J. G., Schroeder, S. R., Buettner, G. R., Wagner, B. A., Du, J., . . . Cullen, J. J. (2018).,
Pharmacological ascorbate reduces radiation-induced normal tissue toxicity and enhances tumor radiosensitization in pancreatic cancer., Cancer Research, doi:canres.1680.2018 [pii]
Li X, Gera L, Zhang S, Chen Y, Lou L, Wilson LM, Xie ZR, Sautto G, Liu D, Danaher A, Mamouni K, Yang Y, Du Y, Fu H, Kucuk O, Osunkoya AO, Zhou J, Wu D.,
Pharmacological inhibition of noncanonical EED-EZH2 signaling overcomes chemoresistance in prostate cancer, Theranostics. 2021 May 8;11(14):6873-6890. doi: 10.7150/thno.49235. eCollection 2021.
Zhang, Y. J., Zhan, X., Wang, L., Ho, R. J., & Sasaki, T. (2015),
pH-responsive artemisinin dimer in lipid nanoparticles are effective against human breast cancer in a xenograft model., Journal of Pharmaceutical Sciences, 104(5), 1815-1824. doi:10.1002/jps.24407 [doi]
Pandya, K., Wyatt, D., Gallagher, B., Shah, D., Baker, A., Bloodworth, J., . . . Osipo, C. (2016).,
PKCalpha attenuates jagged-1-mediated notch signaling in ErbB-2-positive breast cancer to reverse trastuzumab resistance., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(1), 175-186. doi:10.1158/1078-0432.CCR-15-0179 [doi]
Galmarini, C. M., Martin, M., Bouchet, B. P., Guillen-Navarro, M. J., Martinez-Diez, M., Martinez-Leal, J. F., . . . Aviles, P. (2018).,
Plocabulin, a novel tubulin-binding agent, inhibits angiogenesis by modulation of microtubule dynamics in endothelial cells., BMC Cancer, 18(1), 164-018-4086-2. doi:10.1186/s12885-018-4086-2 [doi]
Chen F, Byrd AL, Liu J, Flight RM, DuCote TJ, Naughton KJ, Song X, Edgin AR, Lukyanchuk A, Dixon DT, Gosser CM, Esoe DP, Jayswal RD, Orkin SH, Moseley HNB, Wang C, Brainson CF.,
Polycomb deficiency drives a FOXP2-high aggressive state targetable by epigenetic inhibitors., Nat Commun. 2023 Jan 20;14(1):336. doi: 10.1038/s41467-023-35784-x.
Carlier, C., Strese, S., Viktorsson, K., Velander, E., Nygren, P., Uustalu, M., . . . Gullbo, J. (2016).,
Preclinical activity of melflufen (J1) in ovarian cancer., Oncotarget, 7(37), 59322-59335. doi:10.18632/oncotarget.11163 [doi]
Janku F, Han SW, Doi T, Amatu A, Ajani JA, Kuboki Y, Cortez A, Cellitti SE, Mahling PC, Subramanian K, Schoenfeld HA, Choi SM, Iaconis LA, Lee LH, Pelletier MR, Dranoff G, Askoxylakis V, Siena S.,
Preclinical Characterization and Phase I Study of an Anti-HER2-TLR7 Immune-Stimulator Antibody Conjugate in Patients with HER2+ Malignancies, Cancer Immunol Res. 2022 Dec 2;10(12):1441-1461. doi: 10.1158/2326-6066.CIR-21-0722.
Bähr-Mahmud, H., Ellinghaus, U., Stadler, C. R., Fischer, L., Lindemann, C., Chaturvedi, A., Diekmann, J., Wöll, S., Biermann, I., Hebich, B., Scharf, C., Siefke, M., Roth, A. S., Rao, M., Brettschneider, K., Ewen, E. M., Şahin, U., & Türeci, Ö.,
Preclinical characterization of an mRNA-encoded anti-Claudin 18.2 antibody., Oncoimmunology. 2023 Oct 16;12(1):2255041. doi: 10.1080/2162402X.2023.2255041. eCollection 2023.
Staniszewska AD, Pilger D, Gill SJ, Jamal K, Bohin N, Guzzetti S, Gordon J, Hamm G, Mundin G, Illuzzi G, Pike A, McWilliams L, Maglennon G, Rose J, Hawthorne G, Cortes Gonzalez M, Halldin C, Johnström P, Schou M, Critchlow SE, Fawell S, Johannes JW, et al.,
Preclinical Characterization of AZD9574, a Blood-Brain Barrier Penetrant Inhibitor of PARP1., Clin Cancer Res. 2023 Nov 15. doi: 10.1158/1078-0432.CCR-23-2094. [Epub ahead of print]
Scribner JA, Brown JG, Son T, Chiechi M, Li P, Sharma S, Li H, De Costa A, Li Y, Chen Y, Easton A, Yee-Toy NC, Chen FZ, Gorlatov S, Barat B, Huang L, Wolff CR, Hooley J, Hotaling TE, Gaynutdinov T, Ciccarone V, Tamura J, Koenig S, Moore PA, Bonvini E, Loo D.,
Preclinical Development of MGC018, a Duocarmycin-based Antibody-drug Conjugate Targeting B7-H3 for Solid Cancer, Mol Cancer Ther. 2020 Sep 23:molcanther.0116.2020. doi: 10.1158/1535-7163.MCT-20-0116. Online ahead of print.
Diamond JR, Pitts TM, Ungermannova D, Nasveschuk CG, Zhang G, Phillips AJ, Bagby SM, Pafford J, Yacob BW, Newton TP, Tentler JJ, Gittleman B, Hartman SJ, DeMattei JA, Winkler JD, Wendt MK, Schiemann WP, Eckhardt SG, Liu X, Piscopio AD.,
Preclinical Development of the Class-I-Selective Histone Deacetylase Inhibitor OKI-179 for the Treatment of Solid Tumors, Mol Cancer Ther. 2022 Mar 1;21(3):397-406. doi: 10.1158/1535-7163.MCT-21-0455.
Hammer S, Hagemann UB, Zitzmann-Kolbe S, Larsen A, Ellingsen C, Geraudie S, Grant D, Indrevoll B, Smeets R, von Ahsen O, Kristian A, Lejeune P, Hennekes H, Karlsson J, Bjerke RM, Ryan OB, Cuthbertson AS, Mumberg D.,
Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer, Clin Cancer Res. 2020 Apr 15;26(8):1985-1996. doi: 10.1158/1078-0432.CCR-19-2268. Epub 2019 Dec 12.
Verreault, M., Schmitt, C., Goldwirt, L., Pelton, K., Haidar, S., Levasseur, C., . . . Idbaih, A. (2016).,
Preclinical efficacy of the MDM2 inhibitor RG7112 in MDM2-amplified and TP53 wild-type glioblastomas, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(5), 1185-1196. doi:10.1158/1078-0432.CCR-15-1015 [doi]
Scribner JA, Hicks SW, Sinkevicius KW, Yoder NC, Diedrich G, Brown JG, Lucas J, Fuller ME, Son T, Dastur A, Hooley J, Espelin C, Themeles M, Chen FZ, Li Y, Chiechi M, Lee J, Barat B, Widjaja L, Gorlatov S, Tamura J, Ciccarone V, Ab O, McEachem KA, Koenig S, Westin EH, Moore PA, Chittenden T, Gregory RJ, Bonvini E, Loo D.,
Preclinical Evaluation of IMGC936, a Next-Generation Maytansinoid-based Antibody-drug Conjugate Targeting ADAM9-expressing Tumors, Mol Cancer Ther. 2022 Jul 5;21(7):1047-1059. doi: 10.1158/1535-7163.MCT-21-0915.
Harper, J., Lloyd, C., Dimasi, N., Toader, D., Marwood, R., Lewis, L., . . . Kamal, A. (2017).,
Preclinical evaluation of MEDI0641, a pyrrolobenzodiazepine-conjugated antibody-drug conjugate targeting 5T4., Molecular Cancer Therapeutics, 16(8), 1576-1587. doi:10.1158/1535-7163.MCT-16-0825 [doi]
Waters, A. M., Stewart, J. E., Atigadda, V. R., Mroczek-Musulman, E., Muccio, D. D., Grubbs, C. J., & Beierle, E. A. (2016).,
Preclinical evaluation of UAB30 in pediatric renal and hepatic malignancies., Molecular Cancer Therapeutics, 15(5), 911-921. doi:10.1158/1535-7163.MCT-15-0521 [doi]
Dela Cruz Chuh J, Go M, Chen Y, Guo J, Rafidi H, Mandikian D, Sun Y, Lin Z, Schneider K, Zhang P, Vij R, Sharpnack D, Chan P, de la Cruz C, Sadowsky J, Seshasayee D, Koerber JT, Pillow TH, Phillips GD, Rowntree RK, Boswell CA, Kozak KR, Polson AG, Polakis P, Yu SF, Dragovich PS, Agard NJ.,
Preclinical optimization of Ly6E-targeted ADCs for increased durability and efficacy of anti-tumor response, MAbs. 2021 Jan-Dec;13(1):1862452. doi: 10.1080/19420862.2020.1862452.
Segatto, I., Massarut, S., Boyle, R., Baldassarre, G., Walker, D., & Belletti, B. (2016).,
Preclinical validation of a novel compound targeting p70S6 kinase in breast cancer., Aging, 8(5), 958-976. doi:10.18632/aging.100954 [doi]
Advani, S. J., Buckel, L., Chen, N. G., Scanderbeg, D. J., Geissinger, U., Zhang, Q., . . . Szalay, A. A. (2012).,
Preferential replication of systemically delivered oncolytic vaccinia virus in focally irradiated glioma xenografts, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 18(9), 2579-2590. doi:10.1158/1078-0432.CCR-11-2394 [doi]
Kim SI, Chaurasiya S, Sivanandam V, Kang S, Park AK, Lu J, Yang A, Zhang Z, Bagdasarian IA, Woo Y, Morgan JT, Yin Z, Fong Y, Warner SG.,
Priming stroma with a vitamin D analog to optimize viroimmunotherapy for pancreatic cancer, Mol Ther Oncolytics. 2022 Feb 22;24:864-872. doi: 10.1016/j.omto.2022.02.022. eCollection 2022 Mar 17.
Avasarala, S., Van Scoyk, M., Karuppusamy Rathinam, M. K., Zerayesus, S., Zhao, X., Zhang, W., . . . Bikkavilli, R. K. (2015).,
PRMT1 is a novel regulator of epithelial-mesenchymal-transition in non-small cell lung cancer, The Journal of Biological Chemistry, 290(21), 13479-13489. doi:10.1074/jbc.M114.636050 [doi]
Carter J, Hulse M, Sivakumar M, Burtell J, Thodima V, Wang M, Agarwal A, Vykuntam K, Spruance J, Bhagwat N, Rager J, Ruggeri B, Scherle P, Ito K.,
PRMT5 Inhibitors Regulate DNA Damage Repair Pathways in Cancer Cells and Improve Response to PARP Inhibition and Chemotherapies., Cancer Res Commun. 2023 Nov 6;3(11):2233-2243. doi: 10.1158/2767-9764.CRC-23-0070.
Zhang, Y., Thayele Purayil, H., Black, J. B., Fetto, F., Lynch, L. D., Masannat, J. N., & Daaka, Y. (2017).,
Prostaglandin E2 receptor 4 mediates renal cell carcinoma intravasation and metastasis., Cancer Letters, 391, 50-58. doi:S0304-3835(17)30029-0 [pii]
Dou, Liping; Yan, Fei; Pang, Jiuxia; Zheng, Dehua; Li, Dandan; Gao, Li; Wang, Lijun; Xu, Yihan; Shi, Jinlong; Wang, Qian; Zhou, Lei; Shen, Na; Singh, Puja; Wang, Lili; Li, Yonghui; Gao, Yvchi; Liu, Tao; Chen, Chongjian; Al-Kali, Aref; Litzow, Mark R; Chi, Young-In; Bode, Ann M; Liu, Chunhui; Huang, Haojie; Liu, Daihong; Marcucci, Guido; Liu, Shujun; Yu, Li;,
Protein lysine 43 methylation by EZH1 promotes AML1-ETO transcriptional repression in leukemia., Nature communications Vol.10, 2019
Tozzi M, Sørensen CE, Magni L, Christensen NM, Bouazzi R, Buch CM, Stefanini M, Duranti C, Arcangeli A, Novak I.,
Proton Pump Inhibitors Reduce Pancreatic Adenocarcinoma Progression by Selectively Targeting H(+), K(+)-ATPases in Pancreatic Cancer and Stellate Cells, Cancers (Basel). 2020 Mar 10;12(3):640. doi: 10.3390/cancers12030640.
Kenny HA, Lal-Nag M, Shen M, Kara B, Nahotko DA, Wroblewski K, Fazal S, Chen S, Chiang CY, Chen YJ, Brimacombe KR, Marugan J, Ferrer M, Lengyel E.,
Quantitative High-Throughput Screening Using an Organotypic Model Identifies Compounds that Inhibit Ovarian Cancer Metastasis, Mol Cancer Ther. 2020 Jan;19(1):52-62. doi: 10.1158/1535-7163.MCT-19-0052. Epub 2019 Sep 27.
Gupta K, Vuckovic I, Zhang S, Xiong Y, Carlson BL, Jacobs J, Olson I, Petterson XM, Macura SI, Sarkaria J, Burns TC.,
Radiation Induced Metabolic Alterations Associate With Tumor Aggressiveness and Poor Outcome in Glioblastoma, Front Oncol. 2020 May 5;10:535. doi: 10.3389/fonc.2020.00535. eCollection 2020.
Deshayes, E., Ladjohounlou, R., Le Fur, P., Pichard, A., Lozza, C., Boudousq, V., . . . Pouget, J. P. (2018).,
Radiolabeled antibodies against mullerian-inhibiting substance receptor, type II: New tools for a theranostic approach in ovarian cancer., Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine, 59(8), 1234-1242. doi:10.2967/jnumed.118.208611 [doi]
Jiang, D., Im, H. J., Sun, H., Valdovinos, H. F., England, C. G., Ehlerding, E. B., . . . Cai, W. (2017).,
Radiolabeled pertuzumab for imaging of human epidermal growth factor receptor 2 expression in ovarian cancer., European Journal of Nuclear Medicine and Molecular Imaging, 44(8), 1296-1305. doi:10.1007/s00259-017-3663-y [doi]
Albertoni, C., Leoni, B., Rosi, A., D'Alessio, V., Carollo, V., Spagnoli, L. G., . . . De Santis, R. (2015).,
Radionuclide therapy of unresectable tumors with AvidinOX and (90)Y-biotinDOTA: Tongue cancer paradigm., Cancer Biotherapy & Radiopharmaceuticals, 30(7), 291-298. doi:10.1089/cbr.2015.1837 [doi]
't Hart E, Bianco J, Bruin MAC, Derieppe M, Besse HC, Berkhout K, Chin Joe Kie LA, Su Y, Hoving EW, Huitema ADR, Ries MG, van Vuurden DG.,
Radiosensitisation by olaparib through focused ultrasound delivery in a diffuse midline glioma model., J Control Release. 2023 May;357:287-298. doi: 10.1016/j.jconrel.2023.03.058. Epub 2023 Apr 5.
Houweling M, Abdul UK, Brahm C, Lagerweij T, Heukelom S, Koken PW, Honeywell R, Wedekind LE, Peters GJ, Verheul H, Sminia P, Noske D, Wurdinger T, Westerman BA.,
Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo., J Cancer Res Clin Oncol. 2023 Jan;149(1):297-305. doi: 10.1007/s00432-022-04483-3. Epub 2022 Dec 1.
Schoenfeld, J. D., Sibenaller, Z. A., Mapuskar, K. A., Bradley, M. D., Wagner, B. A., Buettner, G. R., . . . Allen, B. G. (2018).,
Redox active metals and H2O2 mediate the increased efficacy of pharmacological ascorbate in combination with gemcitabine or radiation in pre-clinical sarcoma models., Redox Biology, 14, 417-422. doi:S2213-2317(17)30582-7 [pii]
Mantis, C., Kandela, I., Aird, F., & Reproducibility Project: Cancer Biology. (2017).,
Replication study: Coadministration of a tumor-penetrating peptide enhances the efficacy of cancer drugs., Elife, 6, 10.7554/eLife.17584. doi:10.7554/eLife.17584 [doi]
Kizilbash, S. H., Gupta, S. K., Chang, K., Kawashima, R., Parrish, K. E., Carlson, B. L., . . . Sarkaria, J. N. (2017).,
Restricted delivery of talazoparib across the blood-brain barrier limits the sensitizing effects of PARP inhibition on temozolomide therapy in glioblastoma., Molecular Cancer Therapeutics, 16(12), 2735-2746. doi:10.1158/1535-7163.MCT-17-0365 [doi]
Brown A, Pan Q, Fan L, Indersie E, Tian C, Timchenko N, Li L, Hansen BS, Tan H, Lu M, Peng J, Pruett-Miller SM, Yu J, Cairo S, Zhu L.,
Ribonucleotide Reductase Subunit Switching in Hepatoblastoma Drug Response and Relapse., bioRxiv. 2023 Jan 24. pii: 2023.01.24.525404. doi: 10.1101/2023.01.24.525404. Update in: Commun Biol. 2023 Mar 8;6(1):249.
Smith, Bryan D; Kaufman, Michael D; Lu, Wei-Ping; Gupta, Anu; Leary, Cynthia B; Wise, Scott C; Rutkoski, Thomas J; Ahn, Yu Mi; Al-Ani, Gada; Bulfer, Stacie L; Caldwell, Timothy M; Chun, Lawrence; Ensinger, Carol L; Hood, Molly M; McKinley, Arin; Patt, William C; Ruiz-Soto, Rodrigo; Su, Ying; Telikepalli, Hanumaiah; Town, Ajia; Turner, Benjamin A; Vogeti, Lakshminarayana; Vogeti, Subha; Yates, Karen; Janku, Filip; Abdul Razak, Albiruni Ryan; Rosen, Oliver; Heinrich, Michael C; Flynn, Daniel L;,
Ripretinib (DCC-2618) Is a Switch Control Kinase Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants., Cancer cell Vol.35, 2019
Mi, S., Lin, M., Brouwer-Visser, J., Heim, J., Smotkin, D., Hebert, T., . . . Huang, G. S. (2016),
RNA-seq identification of RACGAP1 as a metastatic driver in uterine carcinosarcoma., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 22(18), 4676-4686. doi:10.1158/1078-0432.CCR-15-2116 [doi]
Cai, Demin; Wang, Junjian; Gao, Bei; Li, Jin; Wu, Feng; Zou, June X; Xu, Jianzhen; Jiang, Yuqian; Zou, Hongye; Huang, Zenghong; Borowsky, Alexander D; Bold, Richard J; Lara, Primo N; Li, Jian Jian; Chen, Xinbin; Lam, Kit S; To, Ka-Fai; Kung, Hsing-Jien; Fiehn, Oliver; Zhao, Ruqian; Evans, Ronald M; Chen, Hong-Wu;,
ROR? is a targetable master regulator of cholesterol biosynthesis in a cancer subtype., Nature communications Vol.10, 2019
Winter, U., Mena, H. A., Negrotto, S., Arana, E., Pascual-Pasto, G., Laurent, V., . . . Schaiquevich, P. (2016).,
Schedule-dependent antiangiogenic and cytotoxic effects of chemotherapy on vascular endothelial and retinoblastoma cells., PloS One, 11(7), e0160094. doi:10.1371/journal.pone.0160094 [doi]
Robles, A. J., Cai, S., Cichewicz, R. H., & Mooberry, S. L. (2016).,
Selective activity of deguelin identifies therapeutic targets for androgen receptor-positive breast cancer., Breast Cancer Research and Treatment, 157(3), 475-488. doi:10.1007/s10549-016-3841-9 [doi]
Yu, Z., He, S., Wang, D., Patel, H. K., Miller, C. P., Brown, J. L., . . . Saeh, J. C. (2017),
Selective androgen receptor modulator RAD140 inhibits the growth of Androgen/Estrogen receptor-positive breast cancer models with a distinct mechanism of action., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(24), 7608-7620. doi:10.1158/1078-0432.CCR-17-0670 [doi]
Kausar, T., Schreiber, J. S., Karnak, D., Parsels, L. A., Parsels, J. D., Davis, M. A., . . . Morgan, M. A. (2015).,
Sensitization of pancreatic cancers to gemcitabine chemoradiation by WEE1 kinase inhibition depends on homologous recombination repair, Neoplasia (New York, N.Y.), 17(10), 757-766. doi:10.1016/j.neo.2015.09.006 [doi]
Gray E, Ulrich M, Epp A, Younan P, Sahetya D, Hensley K, Allred S, Huang LY, Hahn J, Gahnberg K, Treuting PM, Trueblood ES, Gosink JJ, Thurman R, Wo S, Spahr K, Haass EJ, Snead K, Miller D, Padilla M, Smith AJ, Frantz C, et al.,
SGN-B7H4V, an investigational vedotin ADC directed to the immune checkpoint ligand B7-H4, shows promising activity in preclinical models., J Immunother Cancer. 2023 Oct;11(10). pii: e007572. doi: 10.1136/jitc-2023-007572.
Kietzman, William B; Graham, Garrett T; Ory, Virginie; Sharif, Ghada M; Kushner, Max H; Gallanis, Gregory T; Kallakury, Bhaskar; Wellstein, Anton; Riegel, Anna T;,
Short- and Long-Term Effects of CDK4/6 Inhibition on Early-Stage Breast Cancer., Molecular cancer therapeutics Vol.18, 2019
Leelatian, N., Doxie, D. B., Greenplate, A. R., Mobley, B. C., Lehman, J. M., Sinnaeve, J., . . . Irish, J. M. (2017).,
Single cell analysis of human tissues and solid tumors with mass cytometry., Cytometry.Part B, Clinical Cytometry, 92(1), 68-78. doi:10.1002/cyto.b.21481 [doi]
Tchoghandjian, A., Jennewein, C., Eckhardt, I., Momma, S., Figarella-Branger, D., & Fulda, S. (2014).,
Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-kappaB., Cell Death and Differentiation, 21(5), 735-747. doi:10.1038/cdd.2013.200 [doi]
Yoshida, K., Toden, S., Weng, W., Shigeyasu, K., Miyoshi, J., Turner, J., . . . Goel, A. (2017).,
SNORA21 - an oncogenic small nucleolar RNA, with a prognostic biomarker potential in human colorectal cancer., Ebiomedicine, 22, 68-77. doi:S2352-3964(17)30282-7 [pii]
Al-Akhrass H, Pietilä M, Lilja J, Vesilahti EM, Anttila JM, Haikala HM, Munne PM, Klefström J, Peuhu E, Ivaska J.,
Sortilin-related receptor is a druggable therapeutic target in breast cancer, Mol Oncol. 2022 Jan;16(1):116-129. doi: 10.1002/1878-0261.13106. Epub 2021 Oct 10.
Bach, P., Abel, T., Hoffmann, C., Gal, Z., Braun, G., Voelker, I., . . . Buchholz, C. J. (2013).,
Specific elimination of CD133+ tumor cells with targeted oncolytic measles virus., Cancer Research, 73(2), 865-874. doi:10.1158/0008-5472.CAN-12-2221 [doi]
Stossel C, Raitses-Gurevich M, Atias D, Beller T, Glick Gorman Y, Halperin S, Peer E, Denroche RE, Zhang A, Notta F, Wilson JM, O'Kane GM, Haimov Talmoud E, Amison N, Schvimer M, Salpeter SJ, Bar V, Zundelevich A, Tirosh I, Tal R, Dinstag G, Kinar Y, et al.,
Spectrum of Response to Platinum and PARP Inhibitors in Germline BRCA-Associated Pancreatic Cancer in the Clinical and Preclinical Setting., Cancer Discov. 2023 Aug 4;13(8):1826-1843. doi: 10.1158/2159-8290.CD-22-0412.
Hasgur S, Desbourdes L, Relation T, Overholt KM, Stanek JR, Guess AJ, Yu M, Patel P, Roback L, Dominici M, Otsuru S, Horwitz EM.,
Splenic macrophage phagocytosis of intravenously infused mesenchymal stromal cells attenuates tumor localization, Cytotherapy. 2021 May;23(5):411-422. doi: 10.1016/j.jcyt.2020.04.102. Epub 2021 Mar 26.
Li, X., Wu, J. B., Li, Q., Shigemura, K., Chung, L. W., & Huang, W. C. (2016),
SREBP-2 promotes stem cell-like properties and metastasis by transcriptional activation of c-myc in prostate cancer., Oncotarget, 7(11), 12869-12884. doi:10.18632/oncotarget.7331 [doi]
Zhang L, Nesvick CL, Day CA, Choi J, Lu VM, Peterson T, Power EA, Anderson JB, Hamdan FH, Decker PA, Simons R, Welby JP, Siada R, Ge J, Kaptzan T, Johnsen SA, Hinchcliffe EH, Daniels DJ.,
STAT3 is a biologically relevant therapeutic target in H3K27M-mutant diffuse midline glioma, Neuro Oncol. 2022 Oct 3;24(10):1700-1711. doi: 10.1093/neuonc/noac093.
Trotta F, Avena P, Chimento A, Rago V, De Luca A, Sculco S, Nocito MC, Malivindi R, Fallo F, Pezzani R, Pilon C, Lasorsa FM, Barile SN, Palmieri L, Lerario AM, Pezzi V, Casaburi I, Sirianni R.,
Statins Reduce Intratumor Cholesterol Affecting Adrenocortical Cancer Growth, Mol Cancer Ther. 2020 Sep;19(9):1909-1921. doi: 10.1158/1535-7163.MCT-19-1063. Epub 2020 Jun 16.
Gao, F., Alwhaibi, A., Sabbineni, H., Verma, A., Eldahshan, W., & Somanath, P. R. (2017).,
Suppression of Akt1-beta-catenin pathway in advanced prostate cancer promotes TGFbeta1-mediated epithelial to mesenchymal transition and metastasis., Cancer Letters, 402, 177-189. doi:S0304-3835(17)30374-9 [pii]
Vanderburgh, Joseph P; Kwakwa, Kristin A; Werfel, Thomas A; Merkel, Alyssa R; Gupta, Mukesh K; Johnson, Rachelle W; Guelcher, Scott A; Duvall, Craig L; Rhoades, Julie A;,
Systemic delivery of a Gli inhibitor via polymeric nanocarriers inhibits tumor-induced bone disease, Journal of controlled release : official journal of the Controlled Release Society Vol.311-312, 2019
Babae, N., Bourajjaj, M., Liu, Y., Van Beijnum, J. R., Cerisoli, F., Scaria, P. V., . . . Schiffelers, R. M. (2014).,
Systemic miRNA-7 delivery inhibits tumor angiogenesis and growth in murine xenograft glioblastoma., Oncotarget, 5(16), 6687-6700. doi:2235 [pii]
Li M, Liu D, Lee D, Cheng Y, Baumhover NJ, Marks BM, Sagastume EA, Ballas ZK, Johnson FL, Morris ZS, Schultz MK.,
Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma, Cancers (Basel). 2021 Jul 22;13(15):3676. doi: 10.3390/cancers13153676.
Li M, Liu D, Lee D, Cheng Y, Baumhover NJ, Marks BM, Sagastume EA, Ballas ZK, Johnson FL, Morris ZS, Schultz MK.,
Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma, Cancers (Basel). 2021 Jul 22;13(15):3676. doi: 10.3390/cancers13153676.
Rudnick-Glick, S., Corem-Salkmon, E., Grinberg, I., & Margel, S. (2016).,
Targeted drug delivery of near IR fluorescent doxorubicin-conjugated poly(ethylene glycol) bisphosphonate nanoparticles for diagnosis and therapy of primary and metastatic bone cancer in a mouse model., Journal of Nanobiotechnology, 14(1), 80-016-0233-6. doi:10.1186/s12951-016-0233-6 [doi]
Chan, C. M., Jing, X., Pike, L. A., Zhou, Q., Lim, D. J., Sams, S. B., . . . Schweppe, R. E. (2012).,
Targeted inhibition of src kinase with dasatinib blocks thyroid cancer growth and metastasis., . Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 18(13), 3580-3591. doi:10.1158/1078-0432.CCR-11-3359 [doi]
Kandimalla R, Aqil F, Alhakeem SS, Jeyabalan J, Tyagi N, Agrawal A, Yan J, Spencer W, Bondada S, Gupta RC.,
Targeted Oral Delivery of Paclitaxel Using Colostrum-Derived Exosomes, Cancers (Basel). 2021 Jul 23;13(15):3700. doi: 10.3390/cancers13153700.
Kandimalla R, Aqil F, Alhakeem SS, Jeyabalan J, Tyagi N, Agrawal A, Yan J, Spencer W, Bondada S, Gupta RC.,
Targeted Oral Delivery of Paclitaxel Using Colostrum-Derived Exosomes, Cancers (Basel). 2021 Jul 23;13(15):3700. doi: 10.3390/cancers13153700.
Zhang S, Kapoor S, Tripathi C, Perez JT, Mohan N, Dashwood WM, Zhang K, Rajendran P, Dashwood R.,
Targeting ACE2-BRD4 crosstalk in colorectal cancer and the deregulation of DNA repair and apoptosis., NPJ Precis Oncol. 2023 Feb 18;7(1):20. doi: 10.1038/s41698-023-00361-4.
Sen, T., Tong, P., Diao, L., Li, L., Fan, Y., Hoff, J., . . . Byers, L. A. (2017).,
Targeting AXL and mTOR pathway overcomes primary and acquired resistance to WEE1 inhibition in small-cell lung cancer, Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 23(20), 6239-6253. doi:10.1158/1078-0432.CCR-17-1284 [doi]
Ramkumar K, Tanimoto A, Della Corte CM, Stewart CA, Wang Q, Shen L, Cardnell RJ, Wang J, Polanska UM, Andersen C, Saeh J, Pease JE, Travers J, Fabbri G, Gay CM, Urosevic J, Byers LA.,
Targeting BCL2 Overcomes Resistance and Augments Response to Aurora Kinase B Inhibition by AZD2811 in Small Cell Lung Cancer., Clin Cancer Res. 2023 Aug 15;29(16):3237-3249. doi: 10.1158/1078-0432.CCR-23-0375.
Lallous, N., Leblanc, E., Munuganti, R. S., Hassona, M. D., Nakouzi, N. A., Awrey, S., . . . Cherkasov, A. (2016).,
Targeting binding function-3 of the androgen receptor blocks its co-chaperone interactions, nuclear translocation, and activation., Molecular Cancer Therapeutics, 15(12), 2936-2945. doi:1535-7163.MCT-16-0354 [pii]
Dogra S, Elayapillai SP, Qu D, Pitts K, Filatenkov A, Houchen CW, Berry WL, Moxley K, Hannafon BN.,
Targeting doublecortin-like kinase 1 reveals a novel strategy to circumvent chemoresistance and metastasis in ovarian cancer., Cancer Lett. 2023 Dec 1;578:216437. doi: 10.1016/j.canlet.2023.216437. Epub 2023 Oct 12.
Zhao N, Kabotyanski EB, Saltzman AB, Malovannaya A, Yuan X, Reineke LC, Lieu N, Gao Y, Pedroza DA, Calderon SJ, Smith AJ, Hamor C, Safari K, Savage S, Zhang B, Zhou J, Solis LM, Hilsenbeck SG, Fan C, Perou CM, Rosen JM.,
Targeting eIF4A triggers an interferon response to synergize with chemotherapy and suppress triple-negative breast cancer., J Clin Invest. 2023 Dec 15;133(24). pii: e172503. doi: 10.1172/JCI172503.
Pittala, S., Krelin, Y., & Shoshan-Barmatz, V. (2018),
Targeting liver cancer and associated pathologies in mice with a mitochondrial VDAC1-based peptide., Neoplasia (New York, N.Y.), 20(6), 594-609. doi:S1476-5586(17)30508-0 [pii]
de Lucas, A. G., Schuhmacher, A. J., Oteo, M., Romero, E., Camara, J. A., de Martino, A., . . . Mulero, F. (2016),
Targeting MT1-MMP as an ImmunoPET-based strategy for imaging gliomas., PloS One, 11(7), e0158634. doi:10.1371/journal.pone.0158634 [doi]
Stafman, L. L., Mruthyunjayappa, S., Waters, A. M., Garner, E. F., Aye, J. M., Stewart, J. E., . . . Beierle, E. A. (2018).,
Targeting PIM kinase as a therapeutic strategy in human hepatoblastoma., Oncotarget, 9(32), 22665-22679. doi:10.18632/oncotarget.25205 [doi]
Stafman, Laura L; Williams, Adele P; Garner, Evan F; Aye, Jamie M; Stewart, Jerry E; Yoon, Karina J; Whelan, Kimberly; Beierle, Elizabeth A;,
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma., Translational oncology Vol.12, 2019
de Boer, D. V., Martens-de Kemp, S. R., Buijze, M., Stigter-van Walsum, M., Bloemena, E., Dietrich, R., . . . Brakenhoff, R. H. (2017).,
Targeting PLK1 as a novel chemopreventive approach to eradicate preneoplastic mucosal changes in the head and neck., Oncotarget, 8(58), 97928-97940. doi:10.18632/oncotarget.17880 [doi]
Alimova, I., Pierce, A. M., Harris, P., Donson, A., Birks, D. K., Prince, E., . . . Vibhakar, R. (2017).,
Targeting polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor, Oncotarget, 8(57), 97290-97303. doi:10.18632/oncotarget.21932 [doi]
Zhang X, Yao J, Li X, Niu N, Liu Y, Hajek RA, Peng G, Westin S, Sood AK, Liu J.,
Targeting polyploid giant cancer cells potentiates a therapeutic response and overcomes resistance to PARP inhibitors in ovarian cancer., Sci Adv. 2023 Jul 21;9(29):eadf7195. doi: 10.1126/sciadv.adf7195. Epub 2023 Jul 21.
Sorokin AV, Kanikarla Marie P, Bitner L, Syed M, Woods M, Manyam G, Kwong LN, Johnson B, Morris VK, Jones P, Menter DG, Lee MS, Kopetz S.,
Targeting RAS Mutant Colorectal Cancer with Dual Inhibition of MEK and CDK4/6, Cancer Res. 2022 Sep 16;82(18):3335-3344. doi: 10.1158/0008-5472.CAN-22-0198.
Rowell MC, Deschênes-Simard X, Lopes-Paciencia S, Le Calvé B, Kalegari P, Mignacca L, Fernandez-Ruiz A, Guillon J, Lessard F, Bourdeau V, Igelmann S, Duman AM, Stanom Y, Kottakis F, Deshpande V, Krizhanovsky V, Bardeesy N, Ferbeyre G.,
Targeting ribosome biogenesis reinforces ERK-dependent senescence in pancreatic cancer., Cell Cycle. 2023 Oct;22(19):2172-2193. doi: 10.1080/15384101.2023.2278945. Epub 2023 Dec 5.
Sen, M., Joyce, S., Panahandeh, M., Li, C., Thomas, S. M., Maxwell, J., . . . Grandis, J. R. (2012),
Targeting Stat3 abrogates EGFR inhibitor resistance in cancer., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 18(18), 4986-4996. doi:10.1158/1078-0432.CCR-12-0792 [doi]
Jimbo, M., Blanco, F. F., Huang, Y. H., Telonis, A. G., Screnci, B. A., Cosma, G. L., . . . Brody, J. R. (2015),
Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells, Oncotarget, 6(29), 27312-27331. doi:10.18632/oncotarget.4743 [doi]
Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R.,
Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy, Oncogene. 2020 Feb;39(6):1231-1245. doi: 10.1038/s41388-019-1059-0. Epub 2019 Oct 15.
Tocci P, Roman C, Sestito R, Di Castro V, Sacconi A, Molineris I, Paolini F, Carosi M, Tonon G, Blandino G, Bagnato A.,
Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition, Cell Death Dis. 2023 Jan 5;14(1):5. doi: 10.1038/s41419-022-05538-6.
Capone E, Lamolinara A, Pastorino F, Gentile R, Ponziani S, Di Vittorio G, D'Agostino D, Bibbò S, Rossi C, Piccolo E, Iacobelli V, Lattanzio R, Panella V, Sallese M, De Laurenzi V, Giansanti F, Sala A, Iezzi M, Ponzoni M, Ippoliti R, Iacobelli S, Sala G.,
Targeting Vesicular LGALS3BP by an Antibody-Drug Conjugate as Novel Therapeutic Strategy for Neuroblastoma, Cancers (Basel). 2020 Oct 15;12(10):2989. doi: 10.3390/cancers12102989.
Marín-Jiménez JA, Capasso A, Lewis MS, Bagby SM, Hartman SJ, Shulman J, Navarro NM, Yu H, Rivard CJ, Wang X, Barkow JC, Geng D, Kar A, Yingst A, Tufa DM, Dolan JT, Blatchford PJ, Freed BM, Torres RM, Davila E, Slansky JE, Pelanda R, Eckhardt SG, Messersmith WA, Diamond JR, Lieu CH, Verneris MR, Wang JH, Kiseljak-Vassiliades K, Pitts TM, Lang J.,
Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes, Front Immunol. 2021 Mar 29;12:607282. doi: 10.3389/fimmu.2021.607282. eCollection 2021.
Timilsina S, Rajamanickam S, Rao A, Subbarayalu P, Nirzhor S, Abdelfattah N, Viswanadhapalli S, Chen Y, Jatoi I, Brenner A, Rao MK, Vadlamudi R, Kaklamani V.,
The antidepressant imipramine inhibits breast cancer growth by targeting estrogen receptor signaling and DNA repair events, Cancer Lett. 2022 Aug 1;540:215717. doi: 10.1016/j.canlet.2022.215717. Epub 2022 May 12.
Jin, U. H., Lee, S. O., Pfent, C., & Safe, S. (2014).,
The aryl hydrocarbon receptor ligand omeprazole inhibits breast cancer cell invasion and metastasis., BMC Cancer, 14, 498-2407-14-498. doi:10.1186/1471-2407-14-498 [doi]
Bado IL, Zhang W, Hu J, Xu Z, Wang H, Sarkar P, Li L, Wan YW, Liu J, Wu W, Lo HC, Kim IS, Singh S, Janghorban M, Muscarella AM, Goldstein A, Singh P, Jeong HH, Liu C, Schiff R, Huang S, Ellis MJ, Gaber MW, Gugala Z, Liu Z, Zhang XH.,
The bone microenvironment increases phenotypic plasticity of ER(+) breast cancer cells, Dev Cell. 2021 Apr 19;56(8):1100-1117.e9. doi: 10.1016/j.devcel.2021.03.008.
Zhang W, Bado IL, Hu J, Wan YW, Wu L, Wang H, Gao Y, Jeong HH, Xu Z, Hao X, Lege BM, Al-Ouran R, Li L, Li J, Yu L, Singh S, Lo HC, Niu M, Liu J, Jiang W, Li Y, Wong STC, Cheng C, Liu Z, Zhang XH.,
The bone microenvironment invigorates metastatic seeds for further dissemination, Cell. 2021 Apr 29;184(9):2471-2486.e20. doi: 10.1016/j.cell.2021.03.011. Epub 2021 Apr 19.
Morell, C., Bort, A., Vara, D., Ramos-Torres, A., Rodriguez-Henche, N., & Diaz-Laviada, I. (2016).,
The cannabinoid WIN 55,212-2 prevents neuroendocrine differentiation of LNCaP prostate cancer cells., Prostate Cancer and Prostatic Diseases, 19(3), 248-257. doi:10.1038/pcan.2016.19 [doi]
Soukupová J, Bordoni C, Turnham DJ, Yang WW, Seaton G, Gruca A, French R, Lee KY, Varnava A, Piggott L, Clarkson RWE, Westwell AD, Brancale A.,
The Discovery of a Novel Antimetastatic Bcl3 Inhibitor, Mol Cancer Ther. 2021 May;20(5):775-786. doi: 10.1158/1535-7163.MCT-20-0283. Epub 2021 Mar 1.
Anastasia A, Dellavedova G, Ramos-Montoya A, James N, Chiorino G, Russo M, Baakza H, Wilson J, Ghilardi C, Cadogan EB, Giavazzi R, Bani MR.,
The DNA-PK Inhibitor AZD7648 Sensitizes Patient-Derived Ovarian Cancer Xenografts to Pegylated Liposomal Doxorubicin and Olaparib Preventing Abdominal Metastases, Mol Cancer Ther. 2022 Apr 1;21(4):555-567. doi: 10.1158/1535-7163.MCT-21-0420.
Diéguez-Martínez N, Espinosa-Gil S, Yoldi G, Megías-Roda E, Bolinaga-Ayala I, Viñas-Casas M, Gorgisen G, Domingo-Ortí I, Pérez-Montoyo H, Bayascas JR, Colas E, Dolcet X, Lizcano JM.,
The ERK5/NF-κB signaling pathway targets endometrial cancer proliferation and survival, Cell Mol Life Sci. 2022 Sep 19;79(10):524. doi: 10.1007/s00018-022-04541-6.
van Senten, Jeffrey R; Bebelman, Maarten P; Fan, Tian Shu; Heukers, Raimond; Bergkamp, Nick D; van Gasselt, Puck; Langemeijer, Ellen V; Slinger, Erik; Lagerweij, Tonny; Rahbar, Afsar; Stigter-van Walsum, Marijke; Maussang, David; Leurs, Rob; Musters, RenĂŠ J P; van Dongen, Guus A M S; SĂśderberg-NauclĂŠr, Cecilia; WĂźrdinger, Thomas; Siderius, Marco; Smit, Martine J;,
The human cytomegalovirus-encoded G protein-coupled receptor UL33 exhibits oncomodulatory properties, . The Journal of biological chemistry Vol.294, 2019
Laprevotte, E., Cochaud, S., du Manoir, S., Lapierre, M., Dejou, C., Philippe, M., . . . Bonnefoy, N. (2017).,
The IL-17B-IL-17 receptor B pathway promotes resistance to paclitaxel in breast tumors through activation of the ERK1/2 pathway, Oncotarget, 8(69), 113360-113372. doi:10.18632/oncotarget.23008 [doi]
Canon, J., Osgood, T., Olson, S. H., Saiki, A. Y., Robertson, R., Yu, D., . . . Radinsky, R. (2015).,
The MDM2 inhibitor AMG 232 demonstrates robust antitumor efficacy and potentiates the activity of p53-inducing cytotoxic agents, Molecular Cancer Therapeutics, 14(3), 649-658. doi:10.1158/1535-7163.MCT-14-0710 [doi]
Schuller, A. G., Barry, E. R., Jones, R. D., Henry, R. E., Frigault, M. M., Beran, G., . . . D'Cruz, C. M. (2015),
The MET inhibitor AZD6094 (savolitinib, HMPL-504) induces regression in papillary renal cell carcinoma patient-derived xenograft models., Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 21(12), 2811-2819. doi:10.1158/1078-0432.CCR-14-2685 [doi]
Parisotto M, Vuong-Robillard N, Kalegari P, Meharwade T, Joumier L, Igelmann S, Bourdeau V, Rowell MC, Pollak M, Malleshaiah M, Schmitzer A, Ferbeyre G.,
The NAMPT Inhibitor FK866 Increases Metformin Sensitivity in Pancreatic Cancer Cells, Cancers (Basel). 2022 Nov 14;14(22):5597. doi: 10.3390/cancers14225597.
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology Vol.48, 2019,
The novel capsazepine analog, CIDD-99, significantly inhibits oral squamous cell carcinoma in vivo through a TRPV1-independent induction of ER stress, mitochondrial dysfunction, and apoptosis., De La Chapa, Jorge J; Singha, Prajjal K; Self, Kristen K; Sallaway, McKay L; McHardy, Stanton F; Hart, Matthew J; McGuff, Howard Stan; Valdez, Matthew C; Ruiz, Francisco; Polusani, Srikanth R; Gonzales, Cara B;
Kalvala AK, Nimma R, Bagde A, Surapaneni SK, Patel N, Arthur P, Sun L, Singh R, Kommineni N, Nathani A, Li Y, Singh M.,
The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice, Biochimie. 2022 Dec 17;208:19-30. doi: 10.1016/j.biochi.2022.12.008. Online ahead of print.
Kalvala AK, Nimma R, Bagde A, Surapaneni SK, Patel N, Arthur P, Sun L, Singh R, Kommineni N, Nathani A, Li Y, Singh M.,
The role of Cannabidiol and tetrahydrocannabivarin to overcome doxorubicin resistance in MDA-MB-231 xenografts in athymic nude mice., Biochimie. 2023 May;208:19-30. doi: 10.1016/j.biochi.2022.12.008. Epub 2022 Dec 17.
Leal AS, Moerland JA, Zhang D, Carapellucci S, Lockwood B, Krieger-Burke T, Aleiwi B, Ellsworth E, Liby KT.,
The RXR Agonist MSU42011 Is Effective for the Treatment of Preclinical HER2+ Breast Cancer and Kras-Driven Lung Cancer, Cancers (Basel). 2021 Oct 6;13(19):5004. doi: 10.3390/cancers13195004.
Martin-Fernandez, M., Valencia, K., Zandueta, C., Ormazabal, C., Martinez-Canarias, S., Lecanda, F., & de la Piedra, C. (2017),
The usefulness of bone biomarkers for monitoring treatment disease: A comparative study in osteolytic and osteosclerotic bone metastasis models., Translational Oncology, 10(2), 255-261. doi:S1936-5233(16)30223-6 [pii]
Noll A, Myers C, Biery MC, Meechan M, Tahiri S, Rajendran A, Berens ME, Paine D, Byron S, Zhang J, Winter C, Pakiam F, Leary SES, Cole BL, Jackson ER, Dun MD, Foster JB, Evans MK, Pattwell SS, Olson JM, Vitanza NA.,
Therapeutic HDAC inhibition in hypermutant diffuse intrinsic pontine glioma., Neoplasia. 2023 Sep;43:100921. doi: 10.1016/j.neo.2023.100921. Epub 2023 Aug 19.
Kampel L, Goldsmith M, Ramishetti S, Veiga N, Rosenblum D, Gutkin A, Chatterjee S, Penn M, Lerman G, Peer D, Muhanna N.,
Therapeutic inhibitory RNA in head and neck cancer via functional targeted lipid nanoparticles, J Control Release. 2021 Sep 10;337:378-389. doi: 10.1016/j.jconrel.2021.07.034. Epub 2021 Jul 23.
Barbhuiya, M. A., Mirando, A. C., Simons, B. W., Lemtiri-Chlieh, G., Green, J. J., Popel, A. S., . . . Tran, P. T. (2017).,
Therapeutic potential of an anti-angiogenic multimodal biomimetic peptide in hepatocellular carcinoma, Oncotarget, 8(60), 101520-101534. doi:10.18632/oncotarget.21148 [doi]
Wang X, Veeraraghavan J, Liu CC, Cao X, Qin L, Kim JA, Tan Y, Loo SK, Hu Y, Lin L, Lee S, Shea MJ, Mitchell T, Li S, Ellis MJ, Hilsenbeck SG, Schiff R, Wang XS.,
Therapeutic Targeting of Nemo-like Kinase in Primary and Acquired Endocrine-resistant Breast Cancer, Clin Cancer Res. 2021 May 1;27(9):2648-2662. doi: 10.1158/1078-0432.CCR-20-2961. Epub 2021 Feb 4.
Jo U, Murai Y, Agama KK, Sun Y, Saha LK, Yang X, Arakawa Y, Gayle S, Jones K, Paralkar V, Sundaram RK, Van Doorn J, Vasquez JC, Bindra RS, Choi WS, Pommier Y.,
TOP1-DNA Trapping by Exatecan and Combination Therapy with ATR Inhibitor, Mol Cancer Ther. 2022 Jul 5;21(7):1090-1102. doi: 10.1158/1535-7163.MCT-21-1000.
Redko, B., Tuchinsky, H., Segal, T., Tobi, D., Luboshits, G., Ashur-Fabian, O., . . . Gellerman, G. (2017).,
Toward the development of a novel non-RGD cyclic peptide drug conjugate for treatment of human metastatic melanoma, Oncotarget, 8(1), 757-768. doi:10.18632/oncotarget.12748 [doi]
Kiesel, B. F., Parise, R. A., Guo, J., Huryn, D. M., Johnston, P. A., Colombo, R., . . . Eiseman, J. L. (2016).,
Toxicity, pharmacokinetics and metabolism of a novel inhibitor of IL-6-induced STAT3 activation., Cancer Chemotherapy and Pharmacology, 78(6), 1225-1235. doi:10.1007/s00280-016-3181-9 [doi]
Zhang, Z., Li, Z., Wu, X., Zhang, C. F., Calway, T., He, T. C., . . . Yuan, C. S. (2015).,
TRAIL pathway is associated with inhibition of colon cancer by protopanaxadiol., Journal of Pharmacological Sciences, 127(1), 83-91. doi:10.1016/j.jphs.2014.11.003 [doi]
Theunissen, J. W., Cai, A. G., Bhatti, M. M., Cooper, A. B., Avery, A. D., Dorfman, R., . . . Migone, T. S. (2018).,
Treating tissue factor-positive cancers with antibody-drug conjugates that do not affect blood clotting., Molecular Cancer Therapeutics, doi:molcanther.0471.2018 [pii]
Ferraro MG, Bocchetti M, Riccardi C, Trifuoggi M, Paduano L, Montesarchio D, Misso G, Santamaria R, Piccolo M, Irace C.,
Triple Negative Breast Cancer Preclinical Therapeutic Management by a Cationic Ruthenium-Based Nucleolipid Nanosystem., Int J Mol Sci. 2023 Mar 30;24(7). pii: 6473. doi: 10.3390/ijms24076473.
Ostler, K. R., Yang, Q., Looney, T. J., Zhang, L., Vasanthakumar, A., Tian, Y., . . . Godley, L. A. (2012).,
Truncated DNMT3B isoform DNMT3B7 suppresses growth, induces differentiation, and alters DNA methylation in human neuroblastoma., Cancer Research, 72(18), 4714-4723. doi:10.1158/0008-5472.CAN-12-0886 [doi]
Dziegielewska, B., Casarez, E. V., Yang, W. Z., Gray, L. S., Dziegielewski, J., & Slack-Davis, J. K. (2016),
T-type Ca2+ channel inhibition sensitizes ovarian cancer to carboplatin., Molecular Cancer Therapeutics, 15(3), 460-470. doi:10.1158/1535-7163.MCT-15-0456 [doi]
Lingasamy P, Tobi A, Kurm K, Kopanchuk S, Sudakov A, Salumäe M, Rätsep T, Asser T, Bjerkvig R, Teesalu T.,
Tumor-penetrating peptide for systemic targeting of Tenascin-C, Sci Rep. 2020 Apr 2;10(1):5809. doi: 10.1038/s41598-020-62760-y.
Emmenegger, U., Francia, G., Chow, A., Shaked, Y., Kouri, A., Man, S., & Kerbel, R. S. (2011).,
Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide, Neoplasia (New York, N.Y.), 13(1), 40-48.
Brunetti, J., Pillozzi, S., Falciani, C., Depau, L., Tenori, E., Scali, S., . . . Bracci, L. (2015).,
Tumor-selective peptide-carrier delivery of paclitaxel increases in vivo activity of the drug, Scientific Reports, 5, 17736. doi:10.1038/srep17736 [doi]
Gayle S, Aiello R, Leelatian N, Beckta JM, Bechtold J, Bourassa P, Csengery J, Maguire RJ, Marshall D, Sundaram RK, Van Doorn J, Jones K, Moore H, Lopresti-Morrow L, Paradis T, Tylaska L, Zhang Q, Visca H, Reshetnyak YK, Andreev OA, Engelman DM, Glazer PM, Bindra RS, Paralkar VM.,
Tumor-selective, antigen-independent delivery of a pH sensitive peptide-topoisomerase inhibitor conjugate suppresses tumor growth without systemic toxicity, NAR Cancer. 2021 Jun 4;3(2):zcab021. doi: 10.1093/narcan/zcab021. eCollection 2021 Jun.
Petreus T, Cadogan E, Hughes G, Smith A, Pilla Reddy V, Lau A, O'Connor MJ, Critchlow S, Ashford M, Oplustil O'Connor L.,
Tumour-on-chip microfluidic platform for assessment of drug pharmacokinetics and treatment response, Commun Biol. 2021 Aug 24;4(1):1001. doi: 10.1038/s42003-021-02526-y.
González-Rubio S, Salgado C, Manzaneda-González V, Muñoz-Úbeda M, Ahijado-Guzmán R, Natale P, Almendro-Vedia VG, Junquera E, Barcina JO, Ferrer I, Guerrero-Martínez A, Paz-Ares L, López-Montero I.,
Tunable gold nanorod/NAO conjugates for selective drug delivery in mitochondria-targeted cancer therapy, Nanoscale. 2022 Jun 9;14(22):8028-8040. doi: 10.1039/d2nr02353a.
Yuan, B., Cheng, L., Gupta, K., Chiang, H. C., Gupta, H. B., Sareddy, G. R., . . . Li, R. (2016).,
Tyrosine phosphorylation regulates ERbeta ubiquitination, protein turnover, and inhibition of breast cancer., Oncotarget, 7(27), 42585-42597. doi:10.18632/oncotarget.10018 [doi]
Williams, Adele P; Garner, Evan F; Stafman, Laura L; Aye, Jamie M; Quinn, Colin H; Marayati, Raoud; Stewart, Jerry E; Atigadda, Venkatram R; Mroczek-Musulman, Elizabeth; Moore, Blake P; Beierle, Elizabeth A; Friedman, Gregory K;,
UAB30, A Novel Rexinoid Agonist, Decreases Stemness In Group 3 Medulloblastoma Human Cell Line Xenografts., Translational oncology Vol.12, 2019
Nguyen, Tu; Kirsch, Brian James; Asaka, Ryoichi; Nabi, Karim; Quinones, Addison; Tan, Jessica; Antonio, Marjorie Justine; Camelo, Felipe; Li, Ting; Nguyen, Stephanie; Hoang, Giang; Nguyen, Kiet; Udupa, Sunag; Sazeides, Christos; Shen, Yao-An; Elgogary, Amira; Reyes, Juvenal; Zhao, Liang; Kleensang, Andre; Chaichana, Kaisorn Lee; Hartung, Thomas; Betenbaugh, Michael J; Marie, Suely K; Jung, Jin G; Wang, Tian-Li; Gabrielson, Edward; Le, Anne;,
Uncovering the Role of N-Acetyl-Aspartyl-Glutamate as a Glutamate Reservoir in Cance, Cell reports Vol.27, 2019
Lu H, Gomaa A, Wang-Bishop L, Ballout F, Hu T, McDonald O, Washington MK, Livingstone AS, Wang TC, Peng D, El-Rifai W, Chen Z.,
Unfolded Protein Response Is Activated by Aurora Kinase A in Esophageal Adenocarcinoma, Cancers (Basel). 2022 Mar 9;14(6):1401. doi: 10.3390/cancers14061401.
Richter, K., Paakkola, T., Mennerich, D., Kubaichuk, K., Konzack, A., Kippari, H. A., . . . Kietzmann, T. (2018),
USP28 deficiency promotes breast and liver carcinogenesis as well as tumor angiogenesis in a HIF-independent manner., Molecular Cancer Research : MCR, 16(6), 1000-1012. doi:10.1158/1541-7786.MCR-17-0452 [doi]
Gholami, S., Chen, C. H., Lou, E., Belin, L. J., Fujisawa, S., Longo, V. A., . . . Fong, Y. (2014),
Vaccinia virus GLV-1h153 in combination with 131I shows increased efficiency in treating triple-negative breast cancer., FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 28(2), 676-682. doi:10.1096/fj.13-237222 [doi]
Gruslova, A., Cavazos, D. A., Miller, J. R., Breitbart, E., Cohen, Y. C., Bangio, L., . . . Brenner, A. J. (2015).,
VB-111: A novel anti-vascular therapeutic for glioblastoma multiforme, Journal of Neuro-Oncology, 124(3), 365-372. doi:10.1007/s11060-015-1853-7 [doi]
O'Steen, S., Green, D. J., Gopal, A. K., Orozco, J. J., Kenoyer, A. L., Lin, Y., . . . Press, O. W. (2017).,
Venetoclax synergizes with radiotherapy for treatment of B-cell lymphomas., Cancer Research, 77(14), 3885-3893. doi:10.1158/0008-5472.CAN-17-0082 [doi]
Smith BD, Kaufman MD, Wise SC, Ahn YM, Caldwell TM, Leary CB, Lu WP, Tan G, Vogeti L, Vogeti S, Wilky BA, Davis LE, Sharma M, Ruiz-Soto R, Flynn DL.,
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages, Mol Cancer Ther. 2021 Nov;20(11):2098-2109. doi: 10.1158/1535-7163.MCT-21-0361. Epub 2021 Aug 25.
Patil, S. S., Gentschev, I., Adelfinger, M., Donat, U., Hess, M., Weibel, S., . . . Szalay, A. A. (2012).,
Virotherapy of canine tumors with oncolytic vaccinia virus GLV-1h109 expressing an anti-VEGF single-chain antibody, PloS One, 7(10), e47472. doi:10.1371/journal.pone.0047472 [doi]
Kim SI, Chaurasiya S, Park AK, Kang S, Lu J, Woo Y, Yin HH, Yin Z, Fong Y, Warner SG.,
Vitamin D as a Primer for Oncolytic Viral Therapy in Colon Cancer Models, Int J Mol Sci. 2020 Oct 3;21(19):7326. doi: 10.3390/ijms21197326.
Thomson CS, Pundavela J, Perrino MR, Coover RA, Choi K, Chaney KE, Rizvi TA, Largaespada DA, Ratner N.,
WNT5A inhibition alters the malignant peripheral nerve sheath tumor microenvironment and enhances tumor growth, Oncogene. 2021 Jun;40(24):4229-4241. doi: 10.1038/s41388-021-01773-x. Epub 2021 Jun 2.
Stein, A. P., Swick, A. D., Smith, M. A., Blitzer, G. C., Yang, R. Z., Saha, S., . . . Kimple, R. J. (2015).,
Xenograft assessment of predictive biomarkers for standard head and neck cancer therapies, Cancer Medicine, 4(5), 699-712. doi:10.1002/cam4.387 [doi]
Zhang, Q., Sun, X., Yang, J., Ding, H., LeBrun, D., Ding, K., . . . Li, M. (2015).,
ZIP4 silencing improves bone loss in pancreatic cancer., Oncotarget, 6(28), 26041-26051. doi:10.18632/oncotarget.4667 [doi]
Del Vecchio V, Mele L, Panda SK, Sanchez-Pajares IR, Mosca L, Tirino V, Barbieri M, Bruzzese F, Luciano A, Marino FZ, Accardo M, Nicoletti GF, Papaccio G, Barbieri A, Desiderio V.,
β2-AR inhibition enhances EGFR antibody efficacy hampering the oxidative stress response machinery, Cell Death Dis. 2023 Sep 19;14(9):613. doi: 10.1038/s41419-023-06129-9.
Cam M, Charan M, Welker AM, Dravid P, Studebaker AW, Leonard JR, Pierson CR, Nakano I, Beattie CE, Hwang EI, Kambhampati M, Nazarian J, Finlay JL, Cam H.,
ΔNp73/ETS2 complex drives glioblastoma pathogenesis- targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma, Neuro Oncol. 2020 Mar 5;22(3):345-356. doi: 10.1093/neuonc/noz190.